var title_f29_13_29904="Postvenectomy cellulitis";
var content_f29_13_29904=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Postvenectomy cellulitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 199px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cellulitis occurring after saphenous venectomy. The inflammation begins along the medial aspect of the mid-tibial region at the saphenous venectomy site.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Larry M Baddour, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_13_29904=[""].join("\n");
var outline_f29_13_29904=null;
var title_f29_13_29905="Erythrasma in axilla 2";
var content_f29_13_29905=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythrasma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 40-year-old diabetic male presented with red-brown patches in the axillae that resolved with erythromycin therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Jayakar Thomas, MD, PhD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_13_29905=[""].join("\n");
var outline_f29_13_29905=null;
var title_f29_13_29906="Irregular endometrium";
var content_f29_13_29906=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Transvaginal pelvic scan of a patient 19 days since her last episode of bleeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 356px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The endometrial surface is irregular. One surface measures 3.8 mm and the other measures 4.0 mm. An irregular surface is not unusual, particularly in patients who have had previous D&amp;C's, myomectomies, childbirth, etc.; however, the irregular surface of the endometrium identified here as \"moguls\" can be misleading. Performing the procedure this long after the last bleeding episode can be fraught with error and should be avoided.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_13_29906=[""].join("\n");
var outline_f29_13_29906=null;
var title_f29_13_29907="Clioquinol and flumethasone: Drug information";
var content_f29_13_29907=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clioquinol and flumethasone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/0/14341?source=see_link\">",
"    see \"Clioquinol and flumethasone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F183762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Locacorten&reg; Vioform&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F183770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Topical;",
"     </li>",
"     <li>",
"      Corticosteroid, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F183763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Steroid-responsive otic infection:",
"     </b>",
"     Otic solution (drops): Instill 2-3 drops into affected ear(s) 2 times/day; generally limit duration to 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Steroid-responsive dermatoses/infection:",
"     </b>",
"     Topical: Apply in a thin layer to affected area 2-3 times/day; generally limit duration to 7 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F183767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &gt;2 years of age: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15795863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15795864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Locacorten&reg; Vioform&reg;: Clioquinol 3% and flumethasone pivalate 0.02% (15 g, 50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, otic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Locacorten&reg; Vioform&reg;: Clioquinol 1% and flumethasone pivalate 0.02% (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11217383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F183750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Otic solution: Thorough cleaning of the external ear prior to and during therapy either by wiping or gentle syringing is essential.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical cream: Avoid use of occlusive dressings. Cleanse affected area before application; can stain skin and fabrics; for external use only; avoid contact with eyes and mucous membranes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F183749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Otic solution: Treatment of otitis externa; otomycosis due to",
"     <i>",
"      Aspergillus niger",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical cream: Treatment of corticosteroid-responsive dermatoses complicated by infection with bacterial and/or fungal agents",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F183768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, burning, itching, pigmentary changes, purpura, rash, skin atrophy, skin irritation, striae, telangiectasia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine: Potentially associated with excessive/prolonged use: HPA axis suppression (rare), thyrotoxicosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Optic atrophy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity, secondary infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F183753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clioquinol, flumethasone, or any component of the formulation; viral infection of the skin; tuberculosis, syphilis, rosacea, acne vulgaris, or perioral dermatitis; suspected or verified perforation of eardrum (otic solution); application to eyes; application to ulcerated areas (topical); use in children &lt;2 years of age",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F183738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: Systemic absorption of topical corticosteroids may cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Iodine intolerance: Use with caution in patients with iodine intolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Optic atrophy: Known to cause serious and irreversible optic atrophy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral neuropathy: Known to cause serious and peripheral neuropathy with muscular weakness, sensory loss, spastic paraparesis, and blindness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Use with caution in patients with thyroid abnormalities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Topical application poses a potential risk of toxicity to infants and children; striae has been reported with use of some corticosteroids in infants and children. Children may absorb proportionally larger amounts of corticosteroids after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Application site: Do not apply to large areas or denuded skin or use occlusive dressing; may result in increased protein-bound iodine values irritate sensitized skin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate response: Discontinue therapy if no response within 1 week.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F183741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with corticosteroids in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F183764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F183745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe affected area for increased irritation",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F183754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Locacorten-Vioform (DE, DK, FI, NL, NO, SE);",
"     </li>",
"     <li>",
"      Locacorten-Vioform Ear Drops (AU);",
"     </li>",
"     <li>",
"      Locorten Vioform (NZ);",
"     </li>",
"     <li>",
"      Locorten Vioformo (VE);",
"     </li>",
"     <li>",
"      Locorten-Vioformio (BR);",
"     </li>",
"     <li>",
"      Topicorten V (IL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F183737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Flumethasone is a moderate-potency fluorinated corticosteroid; clioquinol chelates bacterial surface and trace metals needed for bacterial growth",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/13/29907/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8576 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-8DAC4F1F78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_13_29907=[""].join("\n");
var outline_f29_13_29907=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183762\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183770\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183763\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183767\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062975\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795863\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795864\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950032\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11217383\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183750\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183749\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183768\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183753\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183738\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299061\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183741\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287205\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183764\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183745\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183754\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183737\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8576\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8576|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/0/14341?source=related_link\">",
"      Clioquinol and flumethasone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_13_29908="Dornase alfa: Drug information";
var content_f29_13_29908=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dornase alfa: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/46/19172?source=see_link\">",
"    see \"Dornase alfa: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/35/26163?source=see_link\">",
"    see \"Dornase alfa: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F161836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pulmozyme&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F161837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pulmozyme&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F161871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Enzyme;",
"     </li>",
"     <li>",
"      Mucolytic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F161839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Mucolytic (cystic fibrosis):",
"     </b>",
"     Inhalation: 2.5 mg daily through selected nebulizers in conjunction with a Pulmo-Aide&reg;, Pari-Proneb&reg;, Mobilaire&trade;, Porta-Neb&reg;, or Pari Baby&trade; compressor system",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients unable to inhale or exhale orally throughout the entire treatment period may use Pari-Baby&trade; nebulizer. Some patients may benefit from twice daily administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Complicated parapneumonic effusion (unlabeled use):",
"     </b>",
"     Intrapleural: 5 mg (diluted in 30 mL sterile water) administered twice daily &gt;2 hours after intrapleural alteplase administration (Rahman, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F161855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/35/26163?source=see_link\">",
"      see \"Dornase alfa: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Mucolytic (cystic fibrosis):",
"     </b>",
"     Inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children &le;5 years: Not approved for use; however, studies using this therapy in small numbers of children as young as 3 months of age have reported efficacy and similar side effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;5 years: 2.5 mg daily through selected nebulizers in conjunction with a Pulmo-Aide&reg;, Pari-Proneb&reg;, Mobilaire&trade;, Porta-Neb&reg;, or Pari Baby&trade; compressor system",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients unable to inhale or exhale orally throughout the entire treatment period may use Pari-Baby&trade; nebulizer. Some patients may benefit from twice daily administration.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F161840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15804875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15804876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F161821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for nebulization [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pulmozyme&reg;: 2.5 mg/2.5 mL (30s) [derived from or manufactured using Chinese hamster ovary  cells]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F161808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F161823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebulization: Prior to use, squeeze each ampul to check for leaks. Should not be diluted or mixed with any other drugs in the nebulizer, this may inactivate the drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parapneumonic effusion (unlabeled use): Intrapleural:",
"     <b>",
"      Note:",
"     </b>",
"     Each dose must be diluted in 30 mL of sterile water. Stability of dornase alfa diluted in sterile water has not been formally evaluated; use immediately after preparation. Instill dose  into chest tube and clamp drain. After 1 hour dwell time, release clamp and connect chest tube to continuous suction (Rahman, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F161876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should not be diluted or mixed with any other drugs in the nebulizer; this may inactivate the dornase alfa.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F161822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of cystic fibrosis patients to reduce the frequency of respiratory infections that require parenteral antibiotics in patients with FVC &ge;40% of predicted; in conjunction with standard therapies, to improve pulmonary function in patients with cystic fibrosis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14328934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infected parapneumonic effusion (following alteplase administration)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F161869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were similar in children using the PARI BABY&trade; nebulizer (facemask as opposed to mouthpiece) with the addition of cough (45% in children 3 months to &lt;5 years; 30% in children 5 to &le;10 years).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (18% to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (32% in patients with FVC &lt;40%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (3% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (32% to 40%), rhinitis (30% in patients with FVC &lt;40%); FVC decrease &ge;10% of predicted (22% in patients with FVC &lt;40%), dyspnea (17% in patients with FVC &lt;40%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Voice alteration (12% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Laryngitis (3% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Dornase alfa serum antibodies (2% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Headache, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F161826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dornase alfa, Chinese hamster ovary cell products, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F161812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Decreased pulmonary function: In patients with pulmonary function &lt;40% of normal, dornase alfa does not significantly reduce the risk of respiratory infections that require parenteral antibiotics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety studies included children &ge;3 months, however experience is limited in children &lt;5 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prolonged therapy: Safety and efficacy have not been established for daily administration &gt;12 months.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6219980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F161818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5131960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F161842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5131961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Measurable amounts would not be expected in breast milk following inhalation; however, it is not known if dornase alfa is excreted in human milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F161828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Pulmozyme Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (2.5 mL): $94.78",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F161829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Pulmozyme (AR, AT, AU, BB, BE, BG, BM, BR, BS, BZ, CH, CO, CZ, DE, DK, ES, FI, FR, GB, GR, GY, HN, HU, IE, IL, IT, JM, LU, MX, NL, NO, PL, PT, RU, SE, SR, TR, TT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F161811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The hallmark of cystic fibrosis lung disease is the presence of abundant, purulent airway secretions composed primarily of highly polymerized DNA. The principal source of this DNA is the nuclei of degenerating neutrophils, which is present in large concentrations in infected lung secretions. The presence of this DNA produces a viscous mucous that may contribute to the decreased mucociliary transport and persistent infections that are commonly seen in this population. Dornase alfa is a deoxyribonuclease (DNA) enzyme produced by recombinant gene technology. Dornase selectively cleaves DNA, thus reducing mucous viscosity and as a result, airflow in the lung is improved and the risk of bacterial infection may be decreased.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F161825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Nebulization: Enzyme levels are measured in sputum in ~15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Rapidly declines",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Albertson TE, Walby WF, Allen RP, et al, &ldquo;The Pharmacology and Toxicology of Three New Biologic Agents Used in Pulmonary Medicine,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1995, 33(5):427-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/13/29908/abstract-text/7650767/pubmed\" id=\"7650767\" target=\"_blank\">",
"        7650767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuchs HJ, Borowitz DS, Christiansen DH, et al, &ldquo;Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients With Cystic Fibrosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1994, 331(10):637-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/13/29908/abstract-text/7503821/pubmed\" id=\"7503821\" target=\"_blank\">",
"        7503821",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hubbard RC, McElvaney NG, Birrer P, et al, &ldquo;A Preliminary Study of Aerosolized Recombinant Human Deoxyribonuclease I in the Treatment of Cystic Fibrosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1992, 326(12):812-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/13/29908/abstract-text/1538726/pubmed\" id=\"1538726\" target=\"_blank\">",
"        1538726",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mueller GA, Rubins G, Wessel D, et al, &ldquo;Effects of Dornase Alfa on Pulmonary Function Tests in Infants with Cystic Fibrosis,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 1996, 153:A70.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rahman NM, Maskell NA, West A, et al, &ldquo;Intrapleural Use of Tissue Plasminogen Activator and DNase in Pleural Infection,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(6):518-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/13/29908/abstract-text/21830966/pubmed\" id=\"21830966\" target=\"_blank\">",
"        21830966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rock M, Kirchner K, McCubbin M, et al, &ldquo;Aerosol Delivery and Safety of rhDNASE in Young Children With Cystic Fibrosis: A Bronchoscopic Study,&rdquo;",
"      <i>",
"       Pediatr Pulmonol",
"      </i>",
"      , 1996, 13(Suppl):A268.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suri R, &ldquo;The Use of Human Deoxyribonuclease (rhDNase) in the Management of Cystic Fibrosis,&rdquo;",
"      <i>",
"       BioDrugs",
"      </i>",
"      , 2005, 19(3):135-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/13/29908/abstract-text/15984899/pubmed\" id=\"15984899\" target=\"_blank\">",
"        15984899",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagener JS, Rock MJ, McCubbin MM, et al, &ldquo;Aerosol Delivery and Safety of Recombinant Human Deoxyribonuclease in Young Children With Cystic Fibrosis: A Bronchoscopic Study. Pulmozyme Pediatric Broncoscopy Study Group,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1998, 133(4):486-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/13/29908/abstract-text/9787685/pubmed\" id=\"9787685\" target=\"_blank\">",
"        9787685",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9385 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-C3C4DA4C00-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_13_29908=[""].join("\n");
var outline_f29_13_29908=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161836\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161837\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161871\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161839\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161855\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161840\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15804875\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15804876\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161821\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161808\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161823\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161876\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161822\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14328934\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161869\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161826\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161812\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299229\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6219980\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161818\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5131960\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161842\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5131961\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161828\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161829\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161811\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161825\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9385\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9385|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/46/19172?source=related_link\">",
"      Dornase alfa: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/35/26163?source=related_link\">",
"      Dornase alfa: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_13_29909="Dolasetron: Pediatric drug information";
var content_f29_13_29909=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dolasetron: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?15/49/16150?source=see_link\">",
"    see \"Dolasetron: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/58/26532?source=see_link\">",
"    see \"Dolasetron: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F162413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Anzemet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F162414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Anzemet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       5-HT",
"       <sub>",
"        3",
"       </sub>",
"       Receptor Antagonist",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiemetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/49/16150?source=see_link\">",
"      see \"Dolasetron: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prevention of chemotherapy-induced nausea and vomiting (CINV): Due to increased risk of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, I.V. use of dolasetron for CINV is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-16 years: Oral: 1.8 mg/kg as a single dose (maximum: 100 mg) within 1 hour before chemotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Oral: 100 mg as a single dose within 1 hour before chemotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postoperative nausea and vomiting:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-16 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prevention:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oral: 1.2 mg/kg within 2 hours before surgery; maximum: 100 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     I.V.: 0.35 mg/kg ~15 minutes before cessation of anesthesia; maximum: 12.5 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: I.V. (only): 0.35 mg/kg as soon as nausea or vomiting present; maximum: 12.5 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prevention:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oral: 100 mg within 2 hours before surgery (doses of 25-200 mg have been used)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     I.V.: 12.5 mg ~15 minutes before cessation of anesthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: I.V. (only): 12.5 mg as soon as nausea or vomiting present",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic or renal impairment:",
"     </b>",
"     No dosage adjustment is necessary",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F162394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as mesylate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anzemet&reg;: 20 mg/mL (0.625 mL, 5 mL, 25 mL) [contains mannitol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as mesylate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anzemet&reg;: 50 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F162379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May be administered with or without food; injection may be administered orally, diluted in apple or apple-grape juice; stable for 2 hours at room temperature",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.V.: Infuse undiluted over 30 seconds or dilute in 50 mL compatible I.V. fluid and infuse over &le;15 minutes; do not mix with other medications; flush line before and after dolasetron administration",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F162448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, LR, and mannitol 10% injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetaminophen, azithromycin, caspofungin, dexmedetomidine, fenoldopam, hetastarch in lactate electrolyte injection (Hextend&reg;), oxaliplatin",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1058126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials and tablets at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) with vial excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light. Injection is stable after dilution in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     1/2NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, LR, and 10% mannitol injection under normal lighting conditions for 24 hours at room temperature and 48 hours under refrigeration",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy (initial and repeat courses), prevention of postoperative nausea and vomiting (FDA approved in ages 2-16 years and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Prevention and treatment of postoperative nausea and vomiting (FDA approved in ages 2-16 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F162450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Anzemet&reg; may be confused with Aldomet, Antivert&reg;, Avandamet&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dolasetron may be confused with granisetron, ondansetron, palonosetron",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F162447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adverse events may vary according to indication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, hypertension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills/shivering, dizziness, fatigue, fever, headache, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, dyspepsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Abnormal hepatic function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Oliguria, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abnormal vision, abnormal dreams, acute renal failure, alkaline phosphatase increased, ALT increased, anaphylactic reaction, anemia, anxiety, AST increased, ataxia, bronchospasm, cardiac arrest, chest pain, confusion, constipation, diaphoresis, dyspnea, dysuria, edema, epistaxis, facial edema, flushing, GGT increased, hematuria, hyperbilirubinemia, hypotension, ischemia (peripheral), local injection site reaction (pain/burning), MI, myocardial ischemia, orthostatic hypotension, palpitation, pancreatitis, paresthesia, peripheral edema, photophobia, polyuria, prothrombin time increased, PTT increased, purpura/hematoma, rash, syncope, taste alteration, thrombocytopenia, thrombophlebitis/phlebitis, tinnitus, tremor, twitching, urticaria, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Cardiac conduction abnormalities (including arrhythmia [sinus, supraventricular and ventricular], atrial flutter/fibrillation, AV block, bundle branch block, extrasystoles, poor R wave progression, prolonged PR, QRS, JT, and QT",
"     <sub>",
"      c",
"     </sub>",
"     intervals, ST, T and U wave changes, torsade de pointes, ventricular tachycardia, wide complex tachycardia and ventricular fibrillation) have also been reported.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dolasetron or any component; use for the prevention of chemotherapy-induced nausea and vomiting (injection only)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1058122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients allergic to other 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     receptor antagonists; cross reactivity has been reported with other 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     receptor antagonists. For chemotherapy associated nausea and vomiting, should be used on a scheduled basis, not on an \"as needed\" (PRN) basis, since data support the use of this drug only in the prevention of nausea and vomiting (due to antineoplastic therapy) and not in the rescue of nausea and vomiting. Not intended for treatment of nausea and vomiting or for chronic continuous therapy.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dolasetron may cause dose-dependent ECG interval changes (eg, PR, QT/QT",
"     <sub>",
"      c",
"     </sub>",
"     , JT prolongation, and QRS widening) related in magnitude and frequency to blood concentrations of the active metabolite, hydrodolasetron; usually occurring 1-2 hours after I.V. administration and usually lasting 6-8 hours; however, may last &ge;24 hours; interval prolongation can lead to cardiovascular consequences, such as heart block or cardiac arrhythmias. Clinically relevant QT interval prolongation may occur, resulting in torsade de pointes, when used in conjunction with other agents that prolong the QT interval (eg, Class I and III antiarrhythmics). Avoid use  in patients at greater risk for QT prolongation, including patients with congenital long QT syndrome, concurrent medication known to prolong QT interval (eg, Class I and III antiarrhythmics), electrolyte abnormalities (ie, hypokalemia, hypomagnesemia) or medications known to reduce potassium or magnesium concentrations (eg, diuretics), and cumulative high-dose anthracycline therapy. Correct potassium or magnesium abnormalities prior to initiating therapy. Parenteral formulation of 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonists have more association with ECG interval changes, compared to oral formulation. Reduction in heart rate may also occur with the 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonists. Use with caution in children and adolescents who have or may develop QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation due to rare reports of supraventricular and ventricular arrhythmias, MI, and cardiac arrest in pediatric and adolescent patients; Canadian healthcare officials have deemed dolasetron contraindicated for the treatment of children and adolescents &lt;18 years of age, and in addition, its use in adults for the treatment of postoperative nausea and vomiting (it has never been indicated for use in children in Canada).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F162437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F162388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apomorphine: Antiemetics (5HT3 Antagonists) may enhance the hypotensive effect of Apomorphine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tapentadol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of Tapentadol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F162390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F759349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1058128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline ECG and serum electrolytes (K, Mg) in high-risk patients",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dolasetron and its major metabolite, hydrodolasetron, are selective 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     receptor antagonists, blocking serotonin, both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1058135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the rapid metabolism of dolasetron to hydrodolasetron (primary active metabolite), the majority of the following pharmacokinetic parameters relate to hydrodolasetron:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 5.9-7.4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 4.15-5.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; rapidly converted by carbonyl reductase to active major metabolite, hydrodolasetron; hydrodolasetron is metabolized by the cytochrome P450 CYP2D6 and CYP3A enzyme systems and flavin mono-oxygenase",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: Children: 59% (formulation not specified), adults: 70% to 80% (not affected by food)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 69% to 77% (active metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dolasetron: &lt;10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrodolasetron:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: Children: 5.7 hours, adults: 8.1 hours (range: 5-10 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: Children: 4.8 hours, adults: 7.3 hours (range: 4-8 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 1-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 0.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Dolasetron: &lt;1% excreted unchanged in urine; hydrodolasetron: 53% to 61% of total dose excreted unchanged in urine within 36 hours",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F5026242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dolasetron injection may be diluted in apple or apple-grape juice and taken orally; this dilution is stable for 2 hours at room temperature (Anzemet&reg; prescribing information, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 10 mg/mL oral suspension may be prepared with tablets and either a 1:1 mixture of Ora-Plus&reg; and Ora-Sweet&reg; SF or a 1:1 mixture of strawberry syrup and Ora-Plus&reg;. Crush twelve 50 mg tablets in a mortar and reduce to a fine powder. Slowly add chosen vehicle to",
"     <b>",
"      almost",
"     </b>",
"     60 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 60 mL. Label \"shake well\" and \"refrigerate\". Stable for 90 days refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Anzemet&reg; prescribing information, sanofi-aventis U.S. LLC, Bridgewater, NJ, 2011.",
"    </div>",
"    <div class=\"reference\">",
"     Johnson CE, Wagner DS, and Bussard WE, \"Stability of Dolasetron in Two Oral Liquid Vehicles,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 2003, 60(21):2242-4.",
"     <span class=\"pubmed-id\">",
"      14619116",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Society of Clinical Oncology, Kris MG, Hesketh PJ, et al, \"American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(18):2932-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/13/29909/abstract-text/16717289/pubmed\" id=\"16717289\" target=\"_blank\">",
"        16717289",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1999, 56(8):729-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/13/29909/abstract-text/10326616 /pubmed\" id=\"10326616 \" target=\"_blank\">",
"        10326616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), \"Clinical Practice Guidelines in Oncology&trade;: Antiemesis,\" Version 4.2009. Available at: file://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olutoye O, Jantzen EC, Alexis R, et al, \"A Comparison of the Costs and Efficacy of Ondansetron and Dolasetron in the Prophylaxis of Postoperative Vomiting in Pediatric Patients Undergoing Ambulatory Surgery,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2003, 97(2):390-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/13/29909/abstract-text/12873923/pubmed\" id=\"12873923\" target=\"_blank\">",
"        12873923",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13246 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-652B83C886-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_13_29909=[""].join("\n");
var outline_f29_13_29909=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162413\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162414\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058129\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058123\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162394\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162379\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058132\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162448\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058126\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058131\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162450\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162447\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058136\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058122\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058121\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162437\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162388\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162390\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F759349\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058128\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058120\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058135\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5026242\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13246\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13246|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/49/16150?source=related_link\">",
"      Dolasetron: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/58/26532?source=related_link\">",
"      Dolasetron: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_13_29910="Rheumatoid nodule Low";
var content_f29_13_29910=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F69272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F69272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rheumatoid nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Biopsy of a nodule from a patient with rheumatoid arthritis showing an area of geographic stellate necrobiosis with extensive fibrin deposition surrounded by a palisading histiocytic rim.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_13_29910=[""].join("\n");
var outline_f29_13_29910=null;
var title_f29_13_29911="Graves eye infiltrate";
var content_f29_13_29911=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F59356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F59356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Graves eye infiltrate: Findings on extraocular muscle biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Disrupted muscle fibers and an area of inflammatory cell accumulation in the superior rectus muscle of a patient with ophthalmic Graves' disease. The sample was obtained at the time of decompression surgery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Terry F Davies, MD, FRCP, FACE.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_13_29911=[""].join("\n");
var outline_f29_13_29911=null;
var title_f29_13_29912="Treatment of blastomycosis";
var content_f29_13_29912=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of blastomycosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/13/29912/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/13/29912/contributors\">",
"     Robert W Bradsher, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/13/29912/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/13/29912/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/13/29912/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/13/29912/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/13/29912/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blastomycosis is a systemic pyogranulomatous infection, primarily involving the lungs, which arises after inhalation of the conidia of Blastomyces dermatitidis. Blastomycosis of the lung can be asymptomatic or manifest as acute or chronic pneumonia. Hematogenous dissemination occurs frequently; extrapulmonary disease of the skin, bones, and genitourinary system is common, but almost any organ can be involved.",
"   </p>",
"   <p>",
"    Unlike acute histoplasmosis, for which treatment often is not necessary, most patients with blastomycosis require therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21881?source=see_link\">",
"     \"Diagnosis and treatment of pulmonary histoplasmosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The antifungal agents proven to be useful in the treatment of blastomycosis will be reviewed here. The approach is generally in keeping with the 2008 IDSA clinical practice guidelines for the treatment of blastomycosis (",
"    <a class=\"graphic graphic_table graphicRef60486 \" href=\"UTD.htm?41/6/42092\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The mycology, pathogenesis, epidemiology, and clinical manifestations of blastomycosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/4/79?source=see_link\">",
"     \"Mycology, pathogenesis, and epidemiology of blastomycosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/57/35736?source=see_link\">",
"     \"Clinical manifestations and diagnosis of blastomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options for patients with blastomycosis include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    or one of the azole drugs (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"     1",
"    </a>",
"    ]. Several factors must be considered when deciding upon the appropriate regimen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical form and severity of disease &mdash; All patients with extrapulmonary disease or progressive pulmonary disease require therapy:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Either a lipid formulation",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      or amphotericin B deoxycholate should be given to patients with moderately severe to severe pulmonary or disseminated infection.",
"     </li>",
"     <li>",
"      A lipid formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      is preferred for patients with central nervous system (CNS) infection.",
"     </li>",
"     <li>",
"      An azole, usually",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      , is preferred for patients with mild to moderate disease not involving the CNS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The immune status of the patient &mdash; Some immunocompetent patients with acute infection confined to the lungs spontaneously clear the infection and may not need treatment. In contrast, all immunocompromised patients should be treated, most frequently with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     STUDIES OF ANTIFUNGALS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Amphotericin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    has broad fungicidal activity against yeasts, molds, and dimorphic fungi, including Blastomyces dermatitidis. Amphotericin B deoxycholate is the agent that has been used most frequently for the treatment of blastomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/3\">",
"     3",
"    </a>",
"    ]. Lipid formulations of amphotericin B are effective in animal models of blastomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/4\">",
"     4",
"    </a>",
"    ], but have not been studied in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"     1",
"    </a>",
"    ]. Despite this limitation, a lipid formulation is generally recommended for the treatment of blastomycosis when amphotericin B is indicated, since lipid formulations have been used extensively and are thought to be as effective as amphotericin B deoxycholate [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/5-8\">",
"     5-8",
"    </a>",
"    ], while being less nephrotoxic and having fewer infusional toxicities [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When administered in cumulative doses greater than 1 g, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate has been reported to result in cure without relapse in 77 to 91 percent of patients with blastomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/9\">",
"     9",
"    </a>",
"    ]. A review of 326 blastomycosis cases over a 10-year period noted a cure rate of 86 percent and a relapse rate of only 4 percent for amphotericin B deoxycholate-treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/10\">",
"     10",
"    </a>",
"    ]. Relapse rates appear to be dose-dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/3,11\">",
"     3,11",
"    </a>",
"    ]. In one series, for example, relapse occurred in 1 of 28 patients who received more than 1.5 g of amphotericin B deoxycholate compared with 6 of 21 patients who received less than 1.5 g [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    deoxycholate therapy is frequently complicated by significant toxicity. A decline in kidney function is the most common serious complication and the most common reason for interruption or premature termination of therapy. Because of reduced nephrotoxicity and better central nervous system (CNS) penetration of one of the lipid formulations in an animal model, lipid preparations of amphotericin B are generally preferred. These are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    (AmBisome) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"     amphotericin B lipid complex",
"    </a>",
"    (Abelcet). Of the lipid formulations, liposomal amphotericin B had the best CNS penetration in a study in rabbits, but it is unknown whether this is associated with greater clinical efficacy in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=see_link\">",
"     \"Amphotericin B nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Azoles",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with moderate or milder forms of blastomycosis, the azoles are safe and effective;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    is the agent used most commonly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Ketoconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     Ketoconazole",
"    </a>",
"    was the first azole proven to be effective for the treatment of immunocompetent patients with nonmeningeal blastomycosis of mild to moderate severity. In a randomized trial conducted by the Mycoses Study Group that compared 400 mg with 800 mg of ketoconazole per day, documented cure rates were 79 and 100 percent in 65 patients treated with ketoconazole at the lower and higher dose, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/13\">",
"     13",
"    </a>",
"    ]. The higher dose was associated with an increased incidence of adverse effects. In other uncontrolled series, ketoconazole, at a dose of 400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or more, produced a cure rate of 76 to 82 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/10,14\">",
"     10,14",
"    </a>",
"    ]. However, relapse of blastomycosis is common after ketoconazole (10 to 14 percent) and toxicity occurs frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/10,13,14\">",
"     10,13,14",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    has replaced ketoconazole as the oral azole of choice, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Itraconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;In comparison to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    , oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    has better absorption, enhanced antifungal activity, and fewer adverse effects. Thus, itraconazole has replaced ketoconazole as the oral azole of choice for the treatment of non-life-threatening, non-CNS blastomycosis. Itraconazole has poor CSF penetration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    was illustrated in a Mycoses Study Group nonrandomized open-label study in which it was effective in 90 percent of 48 patients with blastomycosis treated with daily doses of 200 to 400 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/15\">",
"     15",
"    </a>",
"    ]. In a separate study, only 1 of 42 patients failed the initial course of therapy with 200 mg itraconazole [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/16\">",
"     16",
"    </a>",
"    ]. Four patients later relapsed; two were cured with a second course of itraconazole, and two required treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    . Thus, 39 of 42 patients (93 percent) were eventually cured with itraconazole therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    is generally well tolerated. In the Mycoses Study Group report cited above, treatment was discontinued in only 1 of 48 treated patients because of drug toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/15\">",
"     15",
"    </a>",
"    ]. Side effects include hepatotoxicity, hypokalemia, pedal edema, and, rarely, heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H11#H11\">",
"     \"Pharmacology of azoles\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are important pharmacokinetic differences between the capsule and liquid preparations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    . Absorption of the capsule formulation is highly variable, requires gastric acidity, and is enhanced when the agent is taken with food. Thus, in patients who receive concomitant medications that decrease gastric acidity, blood levels are reduced. In contrast, the liquid formulation has better bioavailability, does not require an acidic environment, and is taken on an empty stomach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H5#H5\">",
"     \"Pharmacology of azoles\", section on 'Pharmacokinetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether the capsule or the liquid formulation is given, monitoring serum levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    in patients after two weeks of treatment is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"     1",
"    </a>",
"    ]. Serum concentrations predictive of failure or success of treatment have not been defined, but serum concentrations of itraconazole greater than 1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    are recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H26#H26\">",
"     \"Pharmacology of azoles\", section on 'Serum drug concentration monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Fluconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only a limited number of patients with blastomycosis have been treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    . The results of a small pilot study employing lower-dose fluconazole were disappointing, with a successful outcome noted in only 65 percent of the 23 patients treated with daily doses of 200 mg and 400 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/17\">",
"     17",
"    </a>",
"    ]. In a second study reporting treatment of 39 patients with daily doses of 400 mg and 800 mg, a successful outcome was noted in 87 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug interactions are less pronounced than those reported for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    . In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    is well absorbed in achlorhydric patients and in those treated with H2 blockers.",
"   </p>",
"   <p>",
"    The efficacy results suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    is not as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    . However, fluconazole has excellent penetration into the CNS and may therefore have some role in the treatment of blastomycotic meningitis and cerebral abscesses in patients who are intolerant of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    . However, only a few patients with CNS blastomycosis have been treated with fluconazole.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Voriconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;B. dermatitidis is susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , and this agent has proven effective in murine models of blastomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Clinical experience is limited.",
"   </p>",
"   <p>",
"    There have been reports of the successful use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    for treatment of refractory blastomycosis and for treatment in immunosuppressed patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/21\">",
"     21",
"    </a>",
"    ]. Voriconazole has also been used as an alternative therapeutic agent in patients who have CNS blastomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/7,22,23\">",
"     7,22,23",
"    </a>",
"    ] based on its ability to achieve therapeutic concentrations in the brain and cerebrospinal fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/24\">",
"     24",
"    </a>",
"    ]. In a multicenter review of 22 CNS cases, an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    formulation was followed by voriconazole in eight patients; all but one patient who received voriconazole had a favorable outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Posaconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;B. dermatitidis is susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    , and this agent has proven effective in murine models of blastomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/26\">",
"     26",
"    </a>",
"    ]. However, posaconazole use has not been reported in human cases of blastomycosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Echinocandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     Caspofungin",
"    </a>",
"    has shown variable activity in vitro against B. dermatitidis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     Micafungin",
"    </a>",
"    is active against the mycelial form, but not the yeast form, of B. dermatitidis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The echinocandins have not been studied in animal models or human cases of blastomycosis and should not be used for the treatment of blastomycosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CHOICE OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike acute histoplasmosis, for which treatment often is not necessary, most patients with blastomycosis require therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21881?source=see_link\">",
"     \"Diagnosis and treatment of pulmonary histoplasmosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment options for patients with blastomycosis include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    or one of the azole drugs (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"     1",
"    </a>",
"    ]. Several factors must be considered when deciding upon the appropriate regimen, such as the clinical form and severity of disease and the immune status of the patient. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'General approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following recommendations reflect the 2008 Infectious Diseases Society of America (IDSA) guidelines for the management of blastomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Guidelines for the management of fungal infections, including blastomycosis, in adult pulmonary and critical care patients have also been published by the American Thoracic Society [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/30\">",
"     30",
"    </a>",
"    ]. These can be accessed at:",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements/resources/mtpi/treatment-of-fungal-infections-in-adult-pulmonary-critical-care-and-sleep-medicine.pdf\">",
"     www.thoracic.org",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pulmonary blastomycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence regarding the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/3,9-11\">",
"     3,9-11",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/15,16\">",
"     15,16",
"    </a>",
"    ] for the treatment of pulmonary blastomycosis comes from small observational studies. Lipid formulations of amphotericin B are effective in animal models of blastomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/4\">",
"     4",
"    </a>",
"    ] but have not been studied in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Moderately severe to severe",
"    </span>",
"    &nbsp;&mdash;&nbsp;A lipid formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously once daily) or amphotericin B deoxycholate (0.7 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously once daily) is the treatment of choice for initial therapy in patients with moderately severe to severe pulmonary blastomycosis (",
"    <a class=\"graphic graphic_table graphicRef60486 \" href=\"UTD.htm?41/6/42092\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"     1",
"    </a>",
"    ]. We prefer a lipid formulation of amphotericin B to avoid the nephrotoxicity of amphotericin B deoxycholate. Once improvement is noted (usually after one to two weeks), therapy can be switched to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (200 mg orally three times daily for three days, followed by twice daily for 6 to 12 months). The serum itraconazole concentration should be measured after at least two weeks of therapy to ensure adequate levels.",
"   </p>",
"   <p>",
"    Rare patients present with fulminant pneumonia and adult respiratory distress syndrome (ARDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Such patients have a mortality rate as high as 50 to 89 percent, and death usually occurs within the first few days of hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/31\">",
"     31",
"    </a>",
"    ]. Treatment with glucocorticoids has been used adjunctively in some patients with ARDS, but there have been no clinical trials to assess whether this is beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1,33\">",
"     1,33",
"    </a>",
"    ]. Further data are needed before the routine use of glucocorticoids can be recommended for patients with fulminant pneumonia and ARDS due to Blastomyces spp.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Mild to moderate",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest treating patients with mild to moderate pulmonary blastomycosis with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (200 mg three times daily for three days, then once or twice daily) for 6 to 12 months (",
"    <a class=\"graphic graphic_table graphicRef60486 \" href=\"UTD.htm?41/6/42092\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"     1",
"    </a>",
"    ]. The serum itraconazole concentration should be measured after at least two weeks of therapy to ensure adequate levels.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    at doses of 400 to 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    can be used as alternatives to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    in patients who are unable to take itraconazole [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"     1",
"    </a>",
"    ]. However, these agents are less effective than itraconazole, and ketoconazole has greater toxicity than either itraconazole or fluconazole. If a patient has progressive pulmonary symptoms on an azole, therapy should be changed to an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , preferably a lipid formulation.",
"   </p>",
"   <p>",
"    Selected immunocompetent patients with mild disease confined to the lungs who are already improving when the diagnosis is established may not require therapy, but must be carefully monitored to ensure that the infection resolves [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/34\">",
"     34",
"    </a>",
"    ]. However, we suggest treating such patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    in an attempt to prevent extrapulmonary disease (",
"    <a class=\"graphic graphic_table graphicRef60486 \" href=\"UTD.htm?41/6/42092\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Disseminated blastomycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence regarding the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/3,9-11\">",
"     3,9-11",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/15,16\">",
"     15,16",
"    </a>",
"    ] for the treatment of disseminated blastomycosis comes from small observational studies; in these studies, only a small subset of patients had disseminated disease. Lipid formulations of amphotericin B are effective in animal models of blastomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/4\">",
"     4",
"    </a>",
"    ] but have not been studied in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All patients with disseminated (extrapulmonary) blastomycosis should be treated. The presence or absence of central nervous system (CNS) infection is the major determinant of the treatment regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Moderately severe to severe disseminated",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderately severe to severe disseminated infection (excluding CNS involvement) should be treated initially with a lipid formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously once daily) or amphotericin B deoxycholate (0.7 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously once daily) for one to two weeks or until improvement is observed (",
"    <a class=\"graphic graphic_table graphicRef60486 \" href=\"UTD.htm?41/6/42092\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"     1",
"    </a>",
"    ]. We prefer a lipid formulation of amphotericin B to avoid the nephrotoxicity of amphotericin B deoxycholate. This should be followed by oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (200 mg three times daily for three days, then 200 mg twice daily) for a total of at least 12 months. The serum itraconazole concentration should be measured after at least two weeks of therapy to ensure adequate levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Mild to moderate disseminated",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mild to moderate disseminated disease (excluding CNS involvement) should be treated with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (200 mg three times daily for three days, then once or twice daily) for 6 to 12 months (",
"    <a class=\"graphic graphic_table graphicRef60486 \" href=\"UTD.htm?41/6/42092\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bone disease is more difficult to treat and more likely to relapse than other forms of blastomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1,35\">",
"     1,35",
"    </a>",
"    ]. Thus, patients with osteoarticular blastomycosis should continue therapy for at least one year [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"     1",
"    </a>",
"    ]. The serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    concentration should be measured after at least two weeks of therapy to ensure adequate levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommendations for treatment of central nervous system (CNS) blastomycosis are based upon case reports and small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/7,8,25\">",
"     7,8,25",
"    </a>",
"    ]. Patients with CNS infection should be treated with a lipid formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) for four to six weeks followed by an oral azole for at least 12 months (",
"    <a class=\"graphic graphic_table graphicRef60486 \" href=\"UTD.htm?41/6/42092\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"     1",
"    </a>",
"    ]. Of the lipid formulations,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    had the best CNS penetration in an animal model, but it is unknown whether this is associated with greater clinical efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not clear which azole is optimal for step-down therapy for CNS blastomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/25\">",
"     25",
"    </a>",
"    ]. Options include high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (800",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (200 mg two to three times daily), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    (200 to 400 mg twice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"     1",
"    </a>",
"    ]. Fluconazole has excellent CNS and cerebrospinal fluid (CSF) penetration but has less activity against B. dermatitidis than the other azoles [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/36\">",
"     36",
"    </a>",
"    ]. There are anecdotal reports of success with fluconazole for the treatment of CNS blastomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    has poor CSF penetration but has greater activity against B. dermatitidis than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"     1",
"    </a>",
"    ]. There are a few case reports of success with itraconazole for the therapy of CNS blastomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    has good CNS and CSF penetration and excellent activity against B. dermatitidis, and has been an effective treatment for CNS blastomycosis in case reports and small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/7,22,23,37\">",
"     7,22,23,37",
"    </a>",
"    ]. No clinical trials have been performed comparing oral azole regimens for step-down therapy of CNS blastomycosis. Based upon the limited data available, we suggest voriconazole for step-down therapy of CNS blastomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/25\">",
"     25",
"    </a>",
"    ]. Because voriconazole exhibits non-linear pharmacokinetics resulting in inter- and intra-patient variability in serum concentrations, monitoring trough concentrations should be considered in patients receiving voriconazole for CNS blastomycosis. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H26#H26\">",
"     \"Pharmacology of azoles\", section on 'Serum drug concentration monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Immunocompromised hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommendations for treatment of blastomycosis in immunocompromised hosts are based upon case reports and small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/6,42-47\">",
"     6,42-47",
"    </a>",
"    ]. Blastomycosis has been reported in patients with advanced HIV infection and in solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Immunocompromised patients with blastomycosis are more likely to present with severe pulmonary or disseminated infection, especially to the central nervous system, and to have a fatal outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1,42,43\">",
"     1,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunocompromised patients with blastomycosis should be treated with a lipid formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously once daily) or amphotericin B deoxycholate (0.7 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously once daily) for one to two weeks or until improvement is observed (",
"    <a class=\"graphic graphic_table graphicRef60486 \" href=\"UTD.htm?41/6/42092\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"     1",
"    </a>",
"    ]. We prefer a lipid formulation of amphotericin B to avoid the nephrotoxicity of amphotericin B deoxycholate.",
"   </p>",
"   <p>",
"    Immunocompromised patients without CNS disease can then be switched to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    therapy (200 mg three times per day for three days, followed by 200 mg bid for 12 months) as step-down therapy. The serum itraconazole concentration should be measured after at least two weeks of therapy to ensure adequate levels.",
"   </p>",
"   <p>",
"    Relapses are common in patients in whom the immunosuppression cannot be reversed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/42,43,48\">",
"     42,43,48",
"    </a>",
"    ]. As a result, long-term suppressive therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with AIDS receiving antiretroviral therapy who have had a CD4 cell count of &gt;150",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    for at least six months can discontinue itraconazole therapy for blastomycosis after a minimum of one year [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"     1",
"    </a>",
"    ]. This recommendation is derived from data demonstrating that it is safe to discontinue itraconazole under these circumstances in AIDS patients with histoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of blastomycosis in pregnancy has not been studied. Pregnant women with blastomycosis should be treated with a lipid formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously once daily) (",
"    <a class=\"graphic graphic_table graphicRef60486 \" href=\"UTD.htm?41/6/42092\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"     1",
"    </a>",
"    ]. The azoles have embryotoxic and teratogenic properties and are therefore contraindicated in pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of blastomycosis is based upon case reports and small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/7,47,50,51\">",
"     7,47,50,51",
"    </a>",
"    ]. Blastomycosis occurs less commonly in children; however, the clinical spectrum of disease and therapeutic considerations are similar to adults [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/50\">",
"     50",
"    </a>",
"    ]. Children tolerate the deoxycholate formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    better than adults.",
"   </p>",
"   <p>",
"    Treatment varies with age and the site of infection (",
"    <a class=\"graphic graphic_table graphicRef60486 \" href=\"UTD.htm?41/6/42092\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neonates with blastomycosis should be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously once daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children with life-threatening or CNS disease should be treated initially with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (0.7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once daily) or a lipid formulation of amphotericin B (3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"       1",
"      </a>",
"      ]. This should be followed by oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, up to 400 mg per day) for a total of twelve months.",
"     </li>",
"     <li>",
"      Children with mild-to-moderate infection without CNS involvement should be treated with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day up to 400 mg per day) for 6 to 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blastomycosis is a systemic pyogranulomatous infection, primarily involving the lungs, that arises after inhalation of the conidia of Blastomyces dermatitidis. Unlike acute histoplasmosis, for which treatment often is not necessary, most patients with blastomycosis require therapy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with mild to moderate disease (pulmonary or extrapulmonary, but excluding CNS disease), we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      rather than another oral antifungal agent or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Mild to moderate'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Mild to moderate disseminated'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with moderately severe to severe disease (pulmonary or extrapulmonary), we recommend initial therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We prefer a lipid formulation of amphotericin B in all patients except children, who tolerate the deoxycholate formulation better than adults do; in patients with CNS disease (including children), we recommend using a lipid formulation (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      After an initial induction phase, we recommend that patients moderately severe to severe disease (except for those with CNS disease) be switched to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      for step-down therapy rather than being continued on amphotericin B&nbsp;(",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Other oral antifungals may also be effective, but the greatest clinical experience is with itraconazole. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Moderately severe to severe'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Moderately severe to severe disseminated'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients with CNS blastomycosis, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      for step-down therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Central nervous system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Appropriate dosing regimens and duration of therapy for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      are discussed above and in the table (",
"      <a class=\"graphic graphic_table graphicRef60486 \" href=\"UTD.htm?41/6/42092\">",
"       table 1",
"      </a>",
"      ). Serum levels of itraconazole should be checked after two weeks of therapy. (See appropriate sections above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/1\">",
"      Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:1801.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.idsociety.org/Content.aspx?id=9088 (Accessed on May 22, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/3\">",
"      Parker JD, Doto IL, Tosh FE. A decade of experience with blastomycosis and its treatment with amphotericin B. A National Communicable Disease Center Cooperative Mycoses Study. Am Rev Respir Dis 1969; 99:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/4\">",
"      Clemons KV, Stevens DA. Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis. Antimicrob Agents Chemother 1991; 35:2144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/5\">",
"      Cook PP. Amphotericin B lipid complex for the treatment of recurrent blastomycosis of the brain in a patient previously treated with itraconazole. South Med J 2001; 94:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/6\">",
"      Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 2005; 40 Suppl 6:S401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/7\">",
"      Panicker J, Walsh T, Kamani N. Recurrent central nervous system blastomycosis in an immunocompetent child treated successfully with sequential liposomal amphotericin B and voriconazole. Pediatr Infect Dis J 2006; 25:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/8\">",
"      Chowfin A, Tight R, Mitchell S. Recurrent blastomycosis of the central nervous system: case report and review. Clin Infect Dis 2000; 30:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/9\">",
"      Bradsher RW. Histoplasmosis and blastomycosis. Clin Infect Dis 1996; 22 Suppl 2:S102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/10\">",
"      Chapman SW, Lin AC, Hendricks KA, et al. Endemic blastomycosis in Mississippi: epidemiological and clinical studies. Semin Respir Infect 1997; 12:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/11\">",
"      Abernathy RS. Amphotericin therapy of North American blastomycosis. Antimicrob Agents Chemother (Bethesda) 1966; 6:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/12\">",
"      Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000; 182:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/13\">",
"      Treatment of blastomycosis and histoplasmosis with ketoconazole. Results of a prospective randomized clinical trial. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Ann Intern Med 1985; 103:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/14\">",
"      Bradsher RW, Rice DC, Abernathy RS. Ketoconazole therapy for endemic blastomycosis. Ann Intern Med 1985; 103:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/15\">",
"      Dismukes WE, Bradsher RW Jr, Cloud GC, et al. Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med 1992; 93:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/16\">",
"      Bradsher RW. Blastomycosis. Clin Infect Dis 1992; 14 Suppl 1:S82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/17\">",
"      Pappas PG, Bradsher RW, Chapman SW, et al. Treatment of blastomycosis with fluconazole: a pilot study. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1995; 20:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/18\">",
"      Pappas PG, Bradsher RW, Kauffman CA, et al. Treatment of blastomycosis with higher doses of fluconazole. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1997; 25:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/19\">",
"      Li RK, Ciblak MA, Nordoff N, et al. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother 2000; 44:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/20\">",
"      Sugar AM, Liu XP. Efficacy of voriconazole in treatment of murine pulmonary blastomycosis. Antimicrob Agents Chemother 2001; 45:601.",
"     </a>",
"    </li>",
"    <li>",
"     Freifeld, A, Proia, LA, Andes, D, et al. Voriconazole use for endemic fungal infections [abstract 572]. In: Program and abstracts of the 44th Annual Meeting of the Infectious Diseases Society of America (Toronto, Canada). Alexandria, VA, Infectious Diseases Society of America, 2006:157.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/22\">",
"      Bakleh M, Aksamit AJ, Tleyjeh IM, Marshall WF. Successful treatment of cerebral blastomycosis with voriconazole. Clin Infect Dis 2005; 40:e69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/23\">",
"      Borgia SM, Fuller JD, Sarabia A, El-Helou P. Cerebral blastomycosis: a case series incorporating voriconazole in the treatment regimen. Med Mycol 2006; 44:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/24\">",
"      Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003; 37:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/25\">",
"      Bariola JR, Perry P, Pappas PG, et al. Blastomycosis of the central nervous system: a multicenter review of diagnosis and treatment in the modern era. Clin Infect Dis 2010; 50:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/26\">",
"      Sugar AM, Liu XP. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother 1996; 40:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/27\">",
"      Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36:2950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/28\">",
"      Zhanel GG, Karlowsky JA, Harding GA, et al. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob Agents Chemother 1997; 41:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/29\">",
"      Nakai T, Uno J, Ikeda F, et al. In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob Agents Chemother 2003; 47:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/30\">",
"      Limper AH, Knox KS, Sarosi GA, et al. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011; 183:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/31\">",
"      Meyer KC, McManus EJ, Maki DG. Overwhelming pulmonary blastomycosis associated with the adult respiratory distress syndrome. N Engl J Med 1993; 329:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/32\">",
"      Lemos LB, Baliga M, Guo M. Acute respiratory distress syndrome and blastomycosis: presentation of nine cases and review of the literature. Ann Diagn Pathol 2001; 5:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/33\">",
"      Lahm T, Neese S, Thornburg AT, et al. Corticosteroids for blastomycosis-induced ARDS: a report of two patients and review of the literature. Chest 2008; 133:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/34\">",
"      Sarosi GA, Davies SF, Phillips JR. Self-limited blastomycosis: a report of 39 cases. Semin Respir Infect 1986; 1:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/35\">",
"      Johnson MD, Perfect JR. Fungal Infections of the Bones and Joints. Curr Infect Dis Rep 2001; 3:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/36\">",
"      Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994; 330:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/37\">",
"      Lentnek, AL, Lentnek, IA. Successful management of Blastomyces dermatitidis meningitis. Infect Med 2006; 23:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/38\">",
"      Taillan B, Ferrari E, Cosnefroy JY, et al. Favourable outcome of blastomycosis of the brain stem with fluconazole and flucytosine treatment. Ann Med 1992; 24:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/39\">",
"      Pearson GJ, Chin TW, Fong IW. Case report: treatment of blastomycosis with fluconazole. Am J Med Sci 1992; 303:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/40\">",
"      Harley WB, Lomis M, Haas DW. Marked polymorphonuclear pleocytosis due to blastomycotic meningitis: case report and review. Clin Infect Dis 1994; 18:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/41\">",
"      Szeder V, Ortega-Gutierrez S, Frank M, Jaradeh SS. CNS blastomycosis in a young man working in fields after Hurricane Katrina. Neurology 2007; 68:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/42\">",
"      Pappas PG, Pottage JC, Powderly WG, et al. Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1992; 116:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/43\">",
"      Pappas PG, Threlkeld MG, Bedsole GD, et al. Blastomycosis in immunocompromised patients. Medicine (Baltimore) 1993; 72:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/44\">",
"      Serody JS, Mill MR, Detterbeck FC, et al. Blastomycosis in transplant recipients: report of a case and review. Clin Infect Dis 1993; 16:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/45\">",
"      Recht LD, Davies SF, Eckman MR, Sarosi GA. Blastomycosis in immunosuppressed patients. Am Rev Respir Dis 1982; 125:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/46\">",
"      Butka BJ, Bennett SR, Johnson AC. Disseminated inoculation blastomycosis in a renal transplant recipient. Am Rev Respir Dis 1984; 130:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/47\">",
"      Linden P, Williams P, Chan KM. Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections. Clin Transplant 2000; 14:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/48\">",
"      Greene NB, Baughman RP, Kim CK, Roselle GA. Failure of ketoconazole in an immunosuppressed patient with pulmonary blastomycosis. Chest 1985; 88:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/49\">",
"      Goldman M, Zackin R, Fichtenbaum CJ, et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis 2004; 38:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/50\">",
"      Schutze GE, Hickerson SL, Fortin EM, et al. Blastomycosis in children. Clin Infect Dis 1996; 22:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29912/abstract/51\">",
"      Morris SK, Brophy J, Richardson SE, et al. Blastomycosis in Ontario, 1994-2003. Emerg Infect Dis 2006; 12:274.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2463 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-BD1901CB76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_13_29912=[""].join("\n");
var outline_f29_13_29912=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      STUDIES OF ANTIFUNGALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Azoles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Ketoconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Itraconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Fluconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Voriconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Posaconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Echinocandins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CHOICE OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pulmonary blastomycosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Moderately severe to severe",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Mild to moderate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Disseminated blastomycosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Moderately severe to severe disseminated",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Mild to moderate disseminated",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2463\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2463|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/6/42092\" title=\"table 1\">",
"      Treatment of blastomycosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=related_link\">",
"      Amphotericin B nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/57/35736?source=related_link\">",
"      Clinical manifestations and diagnosis of blastomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21881?source=related_link\">",
"      Diagnosis and treatment of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/4/79?source=related_link\">",
"      Mycology, pathogenesis, and epidemiology of blastomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_13_29913="Autosomal recessive polycystic kidney disease in children";
var content_f29_13_29913=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Autosomal recessive polycystic kidney disease in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/13/29913/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/13/29913/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/13/29913/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/13/29913/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/13/29913/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/13/29913/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/13/29913/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although renal cysts are present in a wide variety of renal diseases in children, the term polycystic kidney disease is reserved for one of two hereditary conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autosomal recessive polycystic kidney disease (ARPKD, previously called infantile polycystic kidney disease) is a recessively inherited disorder characterized by cystic dilations of the renal collecting ducts and congenital hepatic fibrosis.",
"     </li>",
"     <li>",
"      Autosomal dominant polycystic kidney disease (ADPKD) is a dominantly inherited disorder characterized by cystic dilatations in all parts of the nephron. Cysts in the liver, pancreas, and other organs are also common in ADPKD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and management of ARPKD will be reviewed here. ADPKD and other pediatric renal cystic conditions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28584?source=see_link\">",
"     \"Autosomal dominant polycystic kidney disease in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2712?source=see_link\">",
"     \"Renal cystic diseases in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88678601\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated incidence of ARPKD is 1:10,000 to 1:40,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. However, the true incidence may be higher because severely affected infants may die as newborns without a diagnosis, and patients with mild disease may not be diagnosed until adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/4\">",
"     4",
"    </a>",
"    ]. The carrier frequency for the causative PKHD1 mutation in the general population is reported to be 1:70 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88678691\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ARPKD is caused by mutations in the PKHD1 gene located on chromosome 6p21 and encodes a large protein (4074 amino acids), fibrocystin [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/6\">",
"     6",
"    </a>",
"    ] (also referred to as polyductin [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/7\">",
"     7",
"    </a>",
"    ]). Although the function of fibrocystin is currently unknown, it is found in the cortical and medullary collecting ducts and the thick ascending limb of the kidney, and the epithelial cells of the hepatic bile duct [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/8\">",
"     8",
"    </a>",
"    ]. Fibrocystin localizes to the primary cilia of the kidney collecting ducts along with proteins associated with ADPKD; however, fibrocystin does not share any homology with these [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. This suggests that defects in fibrocystin disrupt normal functioning of renal cilia, pointing toward a shared pathogenesis of cyst formation in the two disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34009?source=see_link\">",
"     \"Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88679525\">",
"    <span class=\"h2\">",
"     Genotype and phenotype correlation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies report a genotype-phenotype correlation in patients with ARPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. Patients with truncation mutations are reported to have more severe renal involvement and early neonatal death than those with one or more missense mutation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 90 patients, all patients with two abnormal alleles associated with a truncated protein had a severe phenotype (eg, perinatal or neonatal death) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 85 affected patients, mutations resulting in a truncated protein encoded from both alleles were strongly associated with neonatal death [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/12\">",
"       12",
"      </a>",
"      ]. By comparison, individuals with at least one mutation resulting in an amino acid substitution were more likely to have milder disease.",
"     </li>",
"     <li>",
"      With mutation analysis of 165 neonatal survivors, not one patient had two truncating mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/10\">",
"       10",
"      </a>",
"      ]. This suggests that cohort newborn survival may require the presence of at least one missense mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/10\">",
"       10",
"      </a>",
"      ], although perinatal death with only one missense mutation has been described [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/13\">",
"       13",
"      </a>",
"      ]. In the study of 165 survivors, missense mutations were associated with milder but variable phenotypes, sometimes resulting in siblings with discordant clinical courses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to the above studies, a study of 73 patients with a wide range of clinical presentation reported severity of PKHD1 mutations and did not predict kidney size or function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/14\">",
"     14",
"    </a>",
"    ]. These patients fulfilled clinical diagnostic criteria, had at least one PKHD1 mutation, and were from 63 independent families. In this cohort, there were 28 patients (28 families) with either one truncating mutation or a combination of a truncating mutation and a missense mutation. The other 45 patients (38 families) had nontruncating variants. The frequency of truncating and missense variants was the same in patients who presented with more severe disease before 30 days of age (perinatal) compared with those with milder disease who presented after 30 days of age (nonperinatal). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, phenotypic variability within a family with the same gene defect has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. In one study, different phenotypic expression was seen in 11 of 20 affected families, including variability at the age of diagnosis and degree of liver and renal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/16\">",
"     16",
"    </a>",
"    ]. Recognition of this variability in disease expression is a potentially important consideration for parents with an affected fetus who are contemplating termination of the pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two organ systems affected in ARPKD are the kidney and liver. Other organ systems, such as the lung and lower extremity deformities, are secondarily involved as a result of kidney",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    liver disease. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88679753\">",
"    <span class=\"h2\">",
"     Kidney",
"    </span>",
"    &nbsp;&mdash;&nbsp;The kidneys are increased in size with microcysts (usually less than three mm in size), which radiate from the medulla to the cortex, and are visible as pinpoint dots on the capsular surface. Histologic examination reveals bilateral cystic dilatations of the collecting tubules, with flattening of the epithelium (",
"    <a class=\"graphic graphic_picture graphicRef73986 \" href=\"UTD.htm?3/44/3783\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef63180 \" href=\"UTD.htm?26/28/27076\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The severity of the renal disease is proportional to the percentage of nephrons affected by cysts. Thus, in patients with milder disease, the ectasia of the collecting tubules is less prominent and irregularly distributed. Larger renal cysts (up to one cm) and interstitial fibrosis may be seen in older patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88679760\">",
"    <span class=\"h2\">",
"     Liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;ARPKD is always associated with some degree of congenital hepatic fibrosis caused by ductal plate malformation of the developing biliary system [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. Histologic examination demonstrates disruption of the ductal plate with portal fibrosis surrounding increased numbers of hyperplastic, ectatic biliary ducts with normal hepatocellular histology. Some patients may have macroscopic dilations of the intrahepatic bile ducts in addition to congenital fibrosis, a combination of findings referred to as Caroli&rsquo;s syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/24\">",
"     24",
"    </a>",
"    ]. The degree of liver involvement varies in ARPKD, but over time, hepatomegaly and portal hypertension develop in most patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2902?source=see_link\">",
"     \"Caroli disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several modes of presentation depending on the age of onset and the predominance of hepatic or renal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/1,4,14,25-27\">",
"     1,4,14,25-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective review from a single center in the United States between 1961 and 2004 illustrates the variability of presentation of patients with ARPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/4\">",
"     4",
"    </a>",
"    ]. Of the 65 cases, including ten patients with isolated hepatic fibrosis, about a third were diagnosed &lt;1 year of age (n = 22), a third between 1 to 20 years of age (n = 23), and a third &gt;20 years of age (n = 20). Patients who were diagnosed in infancy were more likely to present with renal manifestations including renal enlargement, develop endstage renal failure, and have a poor survival rate due to pulmonary insufficiency. Patients who presented later in life were more likely to have manifestations of liver disease including hepatosplenomegaly, hypersplenism, variceal bleeding, cholangitis, and less severe renal involvement. (See",
"    <a class=\"local\" href=\"#H139229729\">",
"     'Renal'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H6\">",
"     'Liver'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9\">",
"     'Outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the previously mentioned retrospective study of 73 patients with confirmed ARPKD who were referred to the National Human Genome Research Institute (NHGRI), 31 patients were diagnosed perinatally (at birth or up to 30 days of life) and had pregnancies complicated by oligohydramnios [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/14\">",
"     14",
"    </a>",
"    ]. In this perinatal group, 27 patients had respiratory distress at birth, including 19 who required mechanical ventilation. The remaining 42 patients (nonperinatal group) presented with symptoms but not respiratory distress after one month of age or were asymptomatic siblings diagnosed by ultrasound.",
"   </p>",
"   <p>",
"    The goal of this NHGRI ongoing intramural research protocol is to obtain longitudinal data on the kidney and liver disease of ARPKD that will provide a basis for more focused studies including therapeutic trials. As of 2010, this protocol is currently recruiting new patients (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00068224?term=arpkd&amp;rank=1\">",
"     NHGRI protocol for ARPKD and CHF",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H139229729\">",
"    <span class=\"h2\">",
"     Renal",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the development of antenatal ultrasonography, most cases of ARPKD are detected prenatally. In severe cases, ARPKD can be detected after 24 weeks of gestation by antenatal ultrasonography which shows markedly enlarged kidneys with increased echogenicity but no visible cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/2,28\">",
"     2,28",
"    </a>",
"    ]. These changes may be accompanied by oligohydramnios and the absence of urine in the fetal bladder. These infants may die early in life from pulmonary insufficiency secondary to pulmonary hypoplasia, with or without the Potter syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/25\">",
"     25",
"    </a>",
"    ]. Less severe cases may not be detected by antenatal ultrasonography. (See",
"    <a class=\"local\" href=\"#H88680828\">",
"     'Potter syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The kidneys increase in size after birth, causing marked abdominal distention. A few years later, however, the kidney growth rate decreases significantly (via an uncertain mechanism that may be related in part to fibrosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/20,29\">",
"     20,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Those children who survive the first month have as much as an 80 percent chance of living beyond 15 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/25,30\">",
"     25,30",
"    </a>",
"    ]. However, they tend to show a progressive increase in clinical manifestations of renal dysfunction that usually begin with signs of tubular dysfunction or injury including [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/29-33\">",
"     29-33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hyponatremia during the first few weeks of life due to the inability to dilute the urine maximally [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduced concentrating ability in most patients with a maximal urine osmolality below 500",
"      <span class=\"nowrap\">",
"       mosmol/kg",
"      </span>",
"     </li>",
"     <li>",
"      Decreased urinary acidification capacity that can lead to metabolic acidosis",
"     </li>",
"     <li>",
"      Recurrent episodes of pyuria",
"     </li>",
"     <li>",
"      Other findings include mild proteinuria, glucosuria, hyperphosphaturia, increased urinary excretion of magnesium, and urinary tract infections [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H139229722\">",
"    <span class=\"h3\">",
"     Renal function impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is variability of renal function amongst patients with ARPKD, progressive renal failure ultimately occurs in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/14,34\">",
"     14,34",
"    </a>",
"    ]. In general, patients who present in the neonatal period have greater impairment of their renal function compared with those who present later in life [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/14,29\">",
"     14,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated in the previously mentioned NHGRI study in which glomerular function rate (GFR) was assessed by two different methods (serum cystatin C and 24 hour creatinine clearance [CrCl]) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/14\">",
"     14",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For perinatally diagnosed patients at a mean age of 9.2 years, the average 24-hour CrCl and the serum-cystatin C-based GFR were 61 and 62",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per m",
"      <sup>",
"       2",
"      </sup>",
"      . In comparison, GFR was higher at an older age in patients who presented after 30 days of life with an average 24-hour CrCl GFR of 103",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per m",
"      <sup>",
"       2",
"      </sup>",
"      and an average serum-cystatin C-based GFR of 89",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per m",
"      <sup>",
"       2",
"      </sup>",
"      .",
"     </li>",
"     <li>",
"      Twenty-five percent of the perinatal group required renal replacement therapy (RRT) by 11 years of age, whereas 25 percent of the nonperinatal group required RRT at 32 years of age.",
"     </li>",
"     <li>",
"      Eight patients with only medullary involvement had normal GFR. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25823482\">",
"    <span class=\"h3\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is common during the first few years, even though the plasma creatinine concentration may be normal or only slightly elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/14,29-31,33\">",
"     14,29-31,33",
"    </a>",
"    ]. It occurs in about two-thirds of children with ARPKD, and is often difficult to control. The underlying pathogenesis may be due to the activation of the local renin-angiotensin system and enhanced sodium retention by the distal collecting ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/35\">",
"     35",
"    </a>",
"    ]. Multiple agents may be required for adequate blood pressure control. Inadequately controlled hypertension may result in cardiac hypertrophy and heart failure, and may contribute to renal function deterioration. In most children, hypertension improves as they get older [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver involvement is always present and may be the predominant clinical feature, especially in older patients. In these cases, renal ultrasonography may be required to detect clinically silent renal disease. Hepatic complications include portal hypertension induced by hepatic fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/23,34,37\">",
"     23,34,37",
"    </a>",
"    ] and acute bacterial cholangitis associated with dilatation of the bile ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with significant liver involvement, the physical examination may reveal an enlarged liver, especially the left lobe under the xiphoid, and the spleen may be palpable in patients who develop portal hypertension.",
"   </p>",
"   <p>",
"    Liver function tests usually remain in the normal range. Ultrasonography of the liver reveals hepatomegaly, increased echogenicity, and dilatation of the peripheral intrahepatic ducts and the main bile ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/38\">",
"     38",
"    </a>",
"    ]. Hepatic cysts may be present and there may also be signs of portal hypertension. Magnetic resonance cholangiography can also visualize nonobstructive dilations of the intrahepatic bile ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ascites and bleeding from esophageal varices are complications that may be seen in patients who develop portal hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88680812\">",
"    <span class=\"h2\">",
"     Lung",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary insufficiency is a major cause of morbidity and mortality in severely affected neonates. These infants typically have pulmonary hypoplasia, and massively enlarged kidney that limit diaphragmatic excursion resulting in hypoventilation and respiratory failure. Oligohydramnios is typically found during pregnancy.",
"   </p>",
"   <p>",
"    Pulmonary hypoplasia is one of the components of Potter syndrome, a composite of findings associated with decreased or absent amniotic fluid (ie, oligohydramnios).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88680828\">",
"    <span class=\"h2\">",
"     Potter syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants or fetuses with severe ARPKD often present with Potter syndrome, which has been used historically to describe the typical findings associated with a fetus or neonate with severe oligohydramnios. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14233?source=see_link\">",
"     \"Oligohydramnios\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This syndrome includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Positional limb deformities (eg, club feet and hip dislocation)",
"     </li>",
"     <li>",
"      Typical facial appearance of pseudoepicanthus, recessed chin, posteriorly rotated, flattened ears, and flattened nose (",
"      <a class=\"graphic graphic_picture graphicRef72847 \" href=\"UTD.htm?22/12/22721\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pulmonary hypoplasia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88680906\">",
"    <span class=\"h2\">",
"     Other findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other findings described in patients with ARPKD include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiomyopathy secondary to hypertension is an uncommon finding in patients with ARPKD [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Feeding difficulties due to fatigue from pulmonary compromise or compression of the stomach by enlarged kidneys, liver, or spleen [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/40\">",
"       40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Thrombocytopenia, which is due to splenic sequestration [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ARPKD is typically based upon clinical, imaging, and laboratory findings. In some cases, when a diagnosis remains uncertain, molecular genetic testing may establish the diagnosis.",
"   </p>",
"   <p>",
"    The clinical diagnosis of ARPKD is based upon satisfying both criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Typical findings on renal imaging",
"     </li>",
"     <li>",
"      One or more of the following findings:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Clinical, laboratory, or imaging signs of hepatic fibrosis",
"     </li>",
"     <li>",
"      Hepatic pathology demonstrating a developmental ductal plate abnormality",
"     </li>",
"     <li>",
"      Absence of renal cysts in both parents, as demonstrated by renal ultrasound, particularly if they are &gt;40 years old",
"     </li>",
"     <li>",
"      Pathoanatomical confirmation of ARPKD in a sibling",
"     </li>",
"     <li>",
"      Parental consanguinity suggestive of autosomal recessive inheritance",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88680805\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88680962\">",
"    <span class=\"h3\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, ultrasonography demonstrates the renal and hepatic imaging findings required for the diagnosis of ARPKD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172118662\">",
"    <span class=\"h4\">",
"     Renal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ultrasound findings of ARPKD are characterized by bilateral large echogenic kidneys with poor corticomedullary differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/42\">",
"     42",
"    </a>",
"    ]. In patients with only medullary involvement, standard-resolution ultrasonography may be normal; however, high-resolution ultrasonography is able to detect ductal dilations confined to the medulla [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/14\">",
"     14",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Macrocysts, typically seen in patients with autosomal dominant disease, are not usually present during infancy but may appear in older children. As a result, in older patients, it may be more challenging to differentiate ARPKD from ADPKD by ultrasound. (See",
"    <a class=\"local\" href=\"#H172118597\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172118669\">",
"    <span class=\"h4\">",
"     Hepatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound findings of the liver include hepatomegaly, increased echogenicity, and dilatation of the peripheral intrahepatic ducts and the main bile ducts. Hepatic cysts may be present and there may also be signs of portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/23,38\">",
"     23,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172118577\">",
"    <span class=\"h3\">",
"     Other modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;If ultrasound results are equivocal, other imaging modalities include magnetic resonance imaging (MRI) and computed tomography (CT) may be useful in the diagnosis of ARPKD.",
"   </p>",
"   <p>",
"    MRI shows enlarged kidneys with hyperintense T-2 weighted singles. RARE- MRI (rapid acquisition with relaxation enhancement) demonstrate microcystic dilatation characterized by a hyperintense, linear radial pattern in the cortex and medulla [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/43\">",
"     43",
"    </a>",
"    ]. MRI also demonstrates the typical hepatic findings of an enlarged liver with bile duct ectasia and portal fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT provides better visualization of the cysts than ultrasound but should not be used initially because of its associated radiation exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172118677\">",
"    <span class=\"h2\">",
"     Molecular genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular genetic testing is based on the observation that ARPKD has only been associated with mutations of the PKHD1 gene.",
"   </p>",
"   <p>",
"    When the clinical criteria for ARPKD are fulfilled, molecular genetic testing is not necessary to confirm the diagnosis. However, molecular genetic testing is used in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diagnosis remains uncertain",
"     </li>",
"     <li>",
"      Prenatal diagnosis",
"     </li>",
"     <li>",
"      Genetic counseling to identify carriers of mutations of the PKHD1 gene",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic testing is available for clinical use and includes the following tests [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mutation scanning using denaturing high-performance liquid chromatography (DHPLC) has an overall detection rate of 85 percent in prenatal diagnosis in affected families [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/13,44-46\">",
"       13,44-46",
"      </a>",
"      ]. Preimplantation diagnosis is possible in some laboratories [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/47\">",
"       47",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=see_link\">",
"       \"Preimplantation genetic diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gene sequencing analyses result in mutation detection rates between 42 and 87 percent depending on the methods used and the proportion of perinatal-onset patients in the cohort [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/48\">",
"       48",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Targeted mutation analysis uses panels of mutations that are specific to certain populations and are available in some laboratories [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Linkage analysis is dependent on the availability of members of an affected family for testing. Markers for linkage analysis are tightly linked to the 6p21 locus and are either intragenic or closely flank PKHD1 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Deletion and duplication analyses are not as useful because few mutations of the PKHD1 gene have been reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Information relating to genetic testing is available through the internet. In particular, GeneReviews, part of the GeneTests web site, are highly structured disease descriptions that help clinicians relate currently available genetic testing to the diagnosis, management, and genetic counseling of patients and families with specific inherited diseases including ARPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/23,38,40\">",
"     23,38,40",
"    </a>",
"    ]. Each GeneReview links directly to the disease-specific clinical laboratory listings in the Laboratory Directory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172118597\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of ARPKD includes the other renal cystic disorders. ARPKD is clinically differentiated from the following disorders by its characteristic renal and hepatic findings, which are typically detected by ultrasonography. In some cases, molecular genetic testing is needed to distinguish ARPKD from the other renal cystic diseases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autosomal dominant polycystic kidney disease (ADPKD) generally presents later than ARPKD. It is a systemic disease with cysts not only in the kidney but in other organs (liver, pancreas, arachnoid membrane, and seminal vesicle) and with non-cystic abnormalities (intracranial aneurysms, cardiac valve disease, colonic diverticula, and abdominal wall and inguinal hernias). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link\">",
"       \"Course and treatment of autosomal dominant polycystic kidney disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=see_link\">",
"       \"Extrarenal manifestations of autosomal dominant polycystic kidney disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28584?source=see_link\">",
"       \"Autosomal dominant polycystic kidney disease in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glomerulocystic kidney disease is a rare disorder that can be a finding in congenital disorders such as tuberous sclerosis, orofacial digital syndrome type 1, trisomy 13, brachymesomelia-renal syndrome, short-rib-polydactyly syndrome, and maturity-onset diabetes of the young [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/40\">",
"       40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43303?source=see_link&amp;anchor=H3#H3\">",
"       \"Renal manifestations of tuberous sclerosis and renal angiomyolipoma\", section on 'Renal lesions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2712?source=see_link&amp;anchor=H7#H7\">",
"       \"Renal cystic diseases in children\", section on 'Glomerular cortical cysts'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88680568\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently, no specific treatment prevents or delays the progression of ARPKD. The management of ARPKD consists of supportive therapy. This includes the management of respiratory distress in affected neonates, and renal replacement therapy in patients who progress to end-stage renal disease (ESRD). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H521057287\">",
"    <span class=\"h2\">",
"     Neonatal respiratory distress",
"    </span>",
"    &nbsp;&mdash;&nbsp;In neonates who present with respiratory distress due to pulmonary hypoplasia, the initial management focuses on supportive respiratory care, which often includes mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/14\">",
"     14",
"    </a>",
"    ]. Reports of unilateral or bilateral nephrectomy have suggested some benefit in patients with severely enlarged kidneys that may compromise lung volume due to restrictive diaphragmatic movement [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/50\">",
"     50",
"    </a>",
"    ]. This may also improve feeding in these infants, who are at-risk for feeding difficulties. However, given that kidney function is preserved for many years even in perinatal-onset ARPKD patients with severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/14\">",
"     14",
"    </a>",
"    ], nephrectomy is not preferred unless it is absolutely necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25823552\">",
"    <span class=\"h2\">",
"     Other supportive measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other management issues in infants who survive the neonatal period with adequate pulmonary function or patients who present after the neonatal period include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyponatremia is a frequent transient manifestation, which should be managed with fluid restriction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27591?source=see_link&amp;anchor=H16#H16\">",
"       \"Fluid and electrolyte therapy in newborns\", section on 'Hyponatremia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=see_link\">",
"       \"Maintenance fluid therapy in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypertension is a common finding. Although multiple agents are often needed for blood pressure control, we begin therapy with an angiotensin-converting enzyme (ACE) inhibitor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42936?source=see_link\">",
"       \"Management of hypertension in infants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Feeding difficulties are also common in the neonate and infant with ARPKD because of limited fluid intake and early stopping of feeding from fatigue or satiety due to gastric compression by the enlarged kidneys. Poor feeding contributes to growth impairment. These infants may require supplemental nasogastric feedings to obtain adequate caloric intake for optimal growth [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/40\">",
"       40",
"      </a>",
"      ]. In some cases, the caloric density of the feeds may be required for limited fluid intake.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25823736\">",
"    <span class=\"h2\">",
"     Renal status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal function is evaluated by measuring serum creatinine (estimated glomerular function rate [GFR]) and obtaining a urinalysis (concentrating ability).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25823743\">",
"    <span class=\"h3\">",
"     Renal replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal replacement therapy (RRT) is needed in patients who develop end-stage renal disease (ESRD). As with all patients with ESRD, the options are either dialysis or renal transplantation, and the choice may be dependent on the clinical setting and expertise of the center caring for the patient.",
"   </p>",
"   <p>",
"    In the neonate with ESRD, dialysis is the only RRT option and needs to be performed in a tertiary center with pediatric expertise in the care of neonates with chronic renal disease (CRD). Both hemodialysis and peritoneal dialysis have been performed in neonates with ARPKD and the choice is dependent on the experience and availability at each center. If peritoneal dialysis is performed, unilateral or bilateral nephrectomy may be needed to accommodate the volume of peritoneal dialysate fluid required for dialysis.",
"   </p>",
"   <p>",
"    Long-term renal transplantation is the preferred therapy in children with ESRD because there is no disease recurrence, and the outcome is excellent particularly regarding growth and quality of life. Nephrectomy may be needed to accommodate the placement of the new graft. In addition, the removal of the native affected kidneys will help in blood pressure control posttransplantation.",
"   </p>",
"   <p>",
"    Children with ARPKD who progress to ESRD are living longer because of RRT. As the lifespan of these patients is extended, they are more likely to develop complications related to congenital hepatic fibrosis, such as portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25823890\">",
"    <span class=\"h2\">",
"     Hepatic status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hepatobiliary system is initially evaluated as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/23,38,40\">",
"     23,38,40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory testing including serum transaminases, hepatic synthetic function (coagulation studies and serum albumin), and complete blood count (platelet count)",
"     </li>",
"     <li>",
"      Physical examination to determine the size of the liver and the presence of a palpable spleen",
"     </li>",
"     <li>",
"      Abdominal ultrasonography to determine the degree of liver involvement",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25823639\">",
"    <span class=\"h2\">",
"     Potential complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management includes preventing, or anticipating and treating the following complications associated with ARPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary tract infections are common in patients with ARPKD. As a result, whenever patients have fever, dysuria, or flank pain, a urine culture should be obtained. Treatment is based on the results of a positive urine culture. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27674?source=see_link&amp;anchor=H2#H2\">",
"       \"Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month\", section on 'Overview'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bacterial cholangitis is a complication seen in patients with more hepatic involvement, and should be considered when patients have persistent fever especially in association with right upper-quadrant pain. Bacterial cholangitis can be the source of recurrent bacteremia with enteric pathogens. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2902?source=see_link&amp;anchor=H4#H4\">",
"       \"Caroli disease\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2902?source=see_link&amp;anchor=H7#H7\">",
"       \"Caroli disease\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Progressive portal hypertension may require porto-caval shunting in patients who still have well-maintained liver function. Liver transplantation is another option for patients being considered for porto-caval shunt. Esophageal varices may be medically treated with a non-selective beta blocker or treated with endoscopic banding or sclerotherapy.",
"     </li>",
"     <li>",
"      Immunization against encapsulated organisms (pneumococcus, H. influenza type B and meningococcus) should be provided for patients with severe portal hypertension and splenic dysfunction.",
"     </li>",
"     <li>",
"      Nephrotoxic drugs (eg, nonsteroidal anti-inflammatory drugs and aminoglycosides) should be avoided.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25823715\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because ARPKD is a progressive disease, the following should be monitored on a regular basis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood pressure measurement  The frequency of evaluation varies depending upon the degree of renal impairment, age of the patient, and the current blood pressure.",
"     </li>",
"     <li>",
"      Renal status function  Renal function should be evaluated at a minimum once a year by monitoring the serum creatinine. The frequency of testing is greater in those with more severe renal involvement.",
"     </li>",
"     <li>",
"      Liver status  Yearly evaluation is performed by physical examination and laboratory testing including complete blood count and liver function studies, and ultrasonography.",
"     </li>",
"     <li>",
"      Growth and nutrition",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25824024\">",
"    <span class=\"h2\">",
"     Counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parents of a child with infantile polycystic kidney disease should be informed that each child or new fetus will have a:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One in four chance of developing the disease (although the expression of the disease may be different in other children)",
"     </li>",
"     <li>",
"      One in two chance of being a carrier",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prenatal genetic screening is possible in families in which the mutation has been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/46,52\">",
"     46,52",
"    </a>",
"    ]. Some studies have reported prenatal mutation detection rates of 70 to 80 percent in families with a range of ARPKD phenotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/3,13\">",
"     3,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the disease-causing mutations cannot be identified, carrier detection using linkage analysis may be possible in families with at least one affected child and in which informative linked markers have been identified. Since this technique is an indirect diagnosis, its accuracy depends upon the correct diagnosis in previously affected siblings [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/52\">",
"     52",
"    </a>",
"    ]. Older asymptomatic siblings of affected children should be evaluated for hepatic fibrosis.",
"   </p>",
"   <p>",
"    Preimplantation diagnosis is also available in some centers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=see_link\">",
"     \"Preimplantation genetic diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25824243\">",
"    <span class=\"h2\">",
"     Future potential therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several promising therapies have been shown to be effective in slowing progressive renal disease in animal models of polycystic kidney diseases and in patients with chronic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/35\">",
"     35",
"    </a>",
"    ]. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Angiotensin blockade with either ACE inhibitors or angiotensin receptor blockers (ARBs)  There is some evidence angiotensin blockade may slow the progression of kidney disease in patients with ADPKD. It is postulated that these agents may have a similar effect in patients with ARPKD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30582?source=see_link&amp;anchor=H3984957#H3984957\">",
"       \"Hypertension in autosomal dominant polycystic kidney disease\", section on 'Choice of agent'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lipid-lowering agents including statins  There is conflicting evidence that the use of statins reduces the progression of renal deterioration in patients with chronic kidney disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30824?source=see_link&amp;anchor=H7#H7\">",
"       \"Statins and chronic kidney disease\", section on 'Statins and kidney function'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link&amp;anchor=H18#H18\">",
"       \"Course and treatment of autosomal dominant polycystic kidney disease\", section on 'Statins'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vasopressin-2 receptor antagonists have been shown to inhibit renal cyst formation and retard progressive renal dysfunction in animal models for ARPKD and ADPKD. Preliminary studies using V2 antagonists in human patients with ADPKD have shown no significant adverse effects associated with their use. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link&amp;anchor=H19#H19\">",
"       \"Course and treatment of autosomal dominant polycystic kidney disease\", section on 'Vasopressin receptor antagonists'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Epidermal growth factor receptor-specific tyrosine kinase inhibitors (EGFR-TKIs) have been shown to retard the progression of liver and kidney disease in mouse models for ARPKD. These agents are small molecules that inhibit autophosphorylation by binding to the intracellular tyrosine kinase domain of EGFR and have been used in the treatment of specific solid tumors in adult patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link&amp;anchor=H23#H23\">",
"       \"Course and treatment of autosomal dominant polycystic kidney disease\", section on 'Other approaches'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, it remains premature to initiate any clinical trial for ARPKD based on the current literature. The NHGRI has set up an ongoing intramural research protocol with a goal of obtaining longitudinal data on the kidney and liver disease of ARPKD that will provide a basis for more focused therapeutic trials that may include some of the above agents. As of 2010, this protocol is currently recruiting new patients (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00068224?term=arpkd&amp;rank=1\">",
"     NHGRI protocol for ARPKD and CHF",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome of ARPKD is dependent on the degree of renal and hepatic involvement, which is most often reflected by the age of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/4,10,30\">",
"     4,10,30",
"    </a>",
"    ]. The mortality rate is greatest for patients who present as neonates with severe renal disease.",
"   </p>",
"   <p>",
"    One review from a single center in the United States divided 65 patients diagnosed with ARPKD from 1961 to 2004 into three age groups at time of diagnosis: &lt;1 year, 1 to 20 years, and &gt;20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the 22 patients less than 1 year of age at diagnosis, 15 had marked enlargement of the kidneys. Six died at or shortly after birth. Of the remaining 16 survivors, eight developed renal insufficiency including six with ESRD. Five patients required treatment for esophageal varices due to portal hypertension, and one patient had cholangitis.",
"     </li>",
"     <li>",
"      Of the 23 patients diagnosed between 1 and 20 years of age, three had renal insufficiency including one with ESRD. The majority had evidence of portal hypertension requiring treatment for esophageal varices in seven, cholangitis in four, and liver transplantation in one.",
"     </li>",
"     <li>",
"      Of the 20 patients diagnosed after 20 years of age, three had renal insufficiency including one with ESRD. Almost all the patients had evidence of liver involvement including five who required treatment for esophageal varices, and five with episodes of cholangitis.",
"     </li>",
"     <li>",
"      The 20-year survival rate was higher for patients diagnosed after one year of age compared to those diagnosed before one year of age (95 versus 75 percent). &nbsp;As noted above, most of the deaths occurred at or shortly before birth.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a German study of 164 patients (from 126 unrelated families), the long-term clinical course of neonatal survivors with ARPKD with defined PKHD1 mutations was reported at a mean followup period of six years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/10\">",
"     10",
"    </a>",
"    ]. The following outcomes were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient survival at one and 10 years was 85 and 82 percent, respectively. Of the 13 deaths, 10 occurred within the first year of life.",
"     </li>",
"     <li>",
"      Renal survival at 5, 10, and 20 years was 86, 71, and 42 percent, respectively.",
"     </li>",
"     <li>",
"      Systemic hypertension developed in approximately 75 percent, while congenital hepatic fibrosis and portal hypertension was observed in 44 percent of the cohort.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As mentioned previously, improved management of renal insufficiency and ESRD has resulted in a greater number of patients developing portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29913/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172118685\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autosomal recessive polycystic kidney disease (ARPKD, previously called infantile polycystic kidney disease) is a recessively inherited disorder characterized by cystic dilations of the renal collecting ducts and congenital hepatic fibrosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The estimated reported incidence of ARPKD is 1:10,000 to 1:40,000, although, this may be an underestimation as severely affected neonates may die without a diagnosis, and young adults with mild disease may not be diagnosed. (See",
"      <a class=\"local\" href=\"#H88678601\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ARPKD is caused by mutations in the PKHD1 gene that encodes for fibrocystin (also referred to as polyductin), which localizes to the primary cilia in the cortical and medullary collecting ducts and the thick ascending limb of the kidney, and the epithelial cells of the hepatic bile duct. (See",
"      <a class=\"local\" href=\"#H88678691\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The renal pathologic findings of ARPKD include enlargement of the kidneys by cystic dilatations (microcysts) of the collecting tubules, and hepatic findings of portal fibrosis with disruption of the ductal plate with hyperplastic, ectatic biliary ducts, and normal liver parenchyma. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations vary with the age of presentation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the neonate, patients present with massively enlarged kidneys, and may have respiratory distress due to pulmonary hypoplasia, and clinical features of Potters syndrome (pulmonary hypoplasia, positional limb deformities, and characteristic facial features (",
"      <a class=\"graphic graphic_picture graphicRef72847 \" href=\"UTD.htm?22/12/22721\">",
"       picture 3",
"      </a>",
"      ) associated with oligohydramnios).",
"     </li>",
"     <li>",
"      Older patients typically have less severe renal disease and more liver involvement, resulting in portal hypertension and an increased risk of cholangitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although renal function varies amongst patients with ARPKD, progressive renal failure occurs in most patients. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Outcome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H139229722\">",
"       'Renal function impairment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two-thirds of patients will have hypertension. (See",
"      <a class=\"local\" href=\"#H25823482\">",
"       'Hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of ARPKD is typically based upon clinical, imaging, and laboratory findings. In some cases, when a diagnosis remains uncertain, molecular genetic testing can establish the diagnosis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of ARPKD includes other renal cystic disorders, such as autosomal dominant polycystic kidney disease. ARPKD is clinically differentiated from other renal cystic disorders by its characteristic renal and liver findings. (See",
"      <a class=\"local\" href=\"#H172118597\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Currently there are no specific interventions that prevent or delay the progression of ARPKD. The management of ARPKD consists of supportive therapy including the management of respiratory distress in affected neonates, and renal replacement therapy in patients who progress to end-stage renal diseases. Counseling includes prenatal genetic testing for interested family members. (See",
"      <a class=\"local\" href=\"#H88680568\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The outcome of ARPKD is dependent on the degree of renal and hepatic involvement, which is often reflected by the age of presentation. The mortality rate is greatest for patients who present as neonates with severe renal disease. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/1\">",
"      Shaikewitz ST, Chapman A. Autosomal recessive polycystic kidney disease: issues regarding the variability of clinical presentation. J Am Soc Nephrol 1993; 3:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/2\">",
"      Zerres K, Hansmann M, Mallmann R, Gembruch U. Autosomal recessive polycystic kidney disease. Problems of prenatal diagnosis. Prenat Diagn 1988; 8:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/3\">",
"      Bergmann C, Senderek J, K&uuml;pper F, et al. PKHD1 mutations in autosomal recessive polycystic kidney disease (ARPKD). Hum Mutat 2004; 23:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/4\">",
"      Adeva M, El-Youssef M, Rossetti S, et al. Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine (Baltimore) 2006; 85:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/5\">",
"      Zerres K, Rudnik-Sch&ouml;neborn S, Steinkamm C, et al. Autosomal recessive polycystic kidney disease. J Mol Med (Berl) 1998; 76:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/6\">",
"      Ward CJ, Hogan MC, Rossetti S, et al. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet 2002; 30:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/7\">",
"      Onuchic LF, Furu L, Nagasawa Y, et al. PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcription-factor domains and parallel beta-helix 1 repeats. Am J Hum Genet 2002; 70:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/8\">",
"      Menezes LF, Cai Y, Nagasawa Y, et al. Polyductin, the PKHD1 gene product, comprises isoforms expressed in plasma membrane, primary cilium, and cytoplasm. Kidney Int 2004; 66:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/9\">",
"      Wang S, Luo Y, Wilson PD, et al. The autosomal recessive polycystic kidney disease protein is localized to primary cilia, with concentration in the basal body area. J Am Soc Nephrol 2004; 15:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/10\">",
"      Bergmann C, Senderek J, Windelen E, et al. Clinical consequences of PKHD1 mutations in 164 patients with autosomal-recessive polycystic kidney disease (ARPKD). Kidney Int 2005; 67:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/11\">",
"      Bergmann C, Senderek J, Sedlacek B, et al. Spectrum of mutations in the gene for autosomal recessive polycystic kidney disease (ARPKD/PKHD1). J Am Soc Nephrol 2003; 14:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/12\">",
"      Furu L, Onuchic LF, Gharavi A, et al. Milder presentation of recessive polycystic kidney disease requires presence of amino acid substitution mutations. J Am Soc Nephrol 2003; 14:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/13\">",
"      Sharp AM, Messiaen LM, Page G, et al. Comprehensive genomic analysis of PKHD1 mutations in ARPKD cohorts. J Med Genet 2005; 42:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/14\">",
"      Gunay-Aygun M, Font-Montgomery E, Lukose L, et al. Correlation of kidney function, volume and imaging findings, and PKHD1 mutations in 73 patients with autosomal recessive polycystic kidney disease. Clin J Am Soc Nephrol 2010; 5:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/15\">",
"      Barth RA, Guillot AP, Capeless EL, Clemmons JJ. Prenatal diagnosis of autosomal recessive polycystic kidney disease: variable outcome within one family. Am J Obstet Gynecol 1992; 166:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/16\">",
"      Deget F, Rudnik-Sch&ouml;neborn S, Zerres K. Course of autosomal recessive polycystic kidney disease (ARPKD) in siblings: a clinical comparison of 20 sibships. Clin Genet 1995; 47:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/17\">",
"      Kaplan BS, Kaplan P, de Chadarevian JP, et al. Variable expression of autosomal recessive polycystic kidney disease and congenital hepatic fibrosis within a family. Am J Med Genet 1988; 29:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/18\">",
"      Holth&ouml;fer H, Kumpulainen T, Rapola J. Polycystic disease of the kidney. Evaluation and classification based on nephron segment and cell-type specific markers. Lab Invest 1990; 62:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/19\">",
"      Kissane JM. Renal cysts in pediatric patients. A classification and overview. Pediatr Nephrol 1990; 4:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/20\">",
"      Lieberman E, Salinas-Madrigal L, Gwinn JL, et al. Infantile polycystic disease of the kidneys and liver: clinical, pathological and radiological correlations and comparison with congenital hepatic fibrosis. Medicine (Baltimore) 1971; 50:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/21\">",
"      Bernstein J. Hepatic involvement in hereditary renal syndromes. Birth Defects Orig Artic Ser 1987; 23:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/22\">",
"      Kamath BM, Piccoli DA. Heritable disorders of the bile ducts. Gastroenterol Clin North Am 2003; 32:857.",
"     </a>",
"    </li>",
"    <li>",
"     Gunay-Aygun, M, Gahl, WA, Heller, T. Congenital hepatic fibrosis overview. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). University of Washington, Seattle. www.genetest.org.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/24\">",
"      Sgro M, Rossetti S, Barozzino T, et al. Caroli's disease: prenatal diagnosis, postnatal outcome and genetic analysis. Ultrasound Obstet Gynecol 2004; 23:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/25\">",
"      Kaplan BS, Kaplan P, Rosenberg HK, et al. Polycystic kidney diseases in childhood. J Pediatr 1989; 115:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/26\">",
"      Rizk D, Chapman AB. Cystic and inherited kidney diseases. Am J Kidney Dis 2003; 42:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/27\">",
"      Parfrey PS. Autosomal-recessive polycystic kidney disease. Kidney Int 2005; 67:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/28\">",
"      Luthy DA, Hirsch JH. Infantile polycystic kidney disease: observations from attempts at prenatal diagnosis. Am J Med Genet 1985; 20:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/29\">",
"      Cole BR, Conley SB, Stapleton FB. Polycystic kidney disease in the first year of life. J Pediatr 1987; 111:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/30\">",
"      Guay-Woodford LM, Desmond RA. Autosomal recessive polycystic kidney disease: the clinical experience in North America. Pediatrics 2003; 111:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/31\">",
"      K&auml;&auml;ri&auml;inen H, Koskimies O, Norio R. Dominant and recessive polycystic kidney disease in children: evaluation of clinical features and laboratory data. Pediatr Nephrol 1988; 2:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/32\">",
"      Gagnadoux MF, Habib R, Levy M, et al. Cystic renal diseases in children. Adv Nephrol Necker Hosp 1989; 18:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/33\">",
"      Kaplan BS, Fay J, Shah V, et al. Autosomal recessive polycystic kidney disease. Pediatr Nephrol 1989; 3:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/34\">",
"      Fonck C, Chauveau D, Gagnadoux MF, et al. Autosomal recessive polycystic kidney disease in adulthood. Nephrol Dial Transplant 2001; 16:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/35\">",
"      Gunay-Aygun M, Avner ED, Bacallao RL, et al. Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis: summary statement of a first National Institutes of Health/Office of Rare Diseases conference. J Pediatr 2006; 149:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/36\">",
"      Mattoo TK, Khatani Y, Ashraf B. Autosomal recessive polycystic kidney disease in 15 Arab children. Pediatr Nephrol 1994; 8:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/37\">",
"      Alvarez F, Bernard O, Brunelle F, et al. Congenital hepatic fibrosis in children. J Pediatr 1981; 99:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/38\">",
"      Turkbey B, Ocak I, Daryanani K, et al. Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis (ARPKD/CHF). Pediatr Radiol 2009; 39:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/39\">",
"      Jung G, Benz-Bohm G, Kugel H, et al. MR cholangiography in children with autosomal recessive polycystic kidney disease. Pediatr Radiol 1999; 29:463.",
"     </a>",
"    </li>",
"    <li>",
"     Dell, KR, Avner, ED, Polycystic kidney disease, autosomal recessive. GeneReviews. 2009. file://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=pkd-ar (Accessed on September 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/41\">",
"      Zerres K, Rudnik-Sch&ouml;neborn S, Deget F, et al. Autosomal recessive polycystic kidney disease in 115 children: clinical presentation, course and influence of gender. Arbeitsgemeinschaft f&uuml;r P&auml;diatrische, Nephrologie. Acta Paediatr 1996; 85:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/42\">",
"      Boal DK, Teele RL. Sonography of infantile polycystic kidney disease. AJR Am J Roentgenol 1980; 135:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/43\">",
"      Kern S, Zimmerhackl LB, Hildebrandt F, et al. Appearance of autosomal recessive polycystic kidney disease in magnetic resonance imaging and RARE-MR-urography. Pediatr Radiol 2000; 30:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/44\">",
"      Bergmann C, K&uuml;pper F, Dornia C, et al. Algorithm for efficient PKHD1 mutation screening in autosomal recessive polycystic kidney disease (ARPKD). Hum Mutat 2005; 25:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/45\">",
"      Bergmann C, Senderek J, Schneider F, et al. PKHD1 mutations in families requesting prenatal diagnosis for autosomal recessive polycystic kidney disease (ARPKD). Hum Mutat 2004; 23:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/46\">",
"      Zerres K, Senderek J, Rudnik-Sch&ouml;neborn S, et al. New options for prenatal diagnosis in autosomal recessive polycystic kidney disease by mutation analysis of the PKHD1 gene. Clin Genet 2004; 66:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/47\">",
"      Gigarel N, Frydman N, Burlet P, et al. Preimplantation genetic diagnosis for autosomal recessive polycystic kidney disease. Reprod Biomed Online 2008; 16:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/48\">",
"      Gunay-Aygun M, Tuchman M, Font-Montgomery E, et al. PKHD1 sequence variations in 78 children and adults with autosomal recessive polycystic kidney disease and congenital hepatic fibrosis. Mol Genet Metab 2010; 99:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/49\">",
"      Consugar MB, Anderson SA, Rossetti S, et al. Haplotype analysis improves molecular diagnostics of autosomal recessive polycystic kidney disease. Am J Kidney Dis 2005; 45:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/50\">",
"      Shukla AR, Kiddoo DA, Canning DA. Unilateral nephrectomy as palliative therapy in an infant with autosomal recessive polycystic kidney disease. J Urol 2004; 172:2000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/51\">",
"      Khan K, Schwarzenberg SJ, Sharp HL, et al. Morbidity from congenital hepatic fibrosis after renal transplantation for autosomal recessive polycystic kidney disease. Am J Transplant 2002; 2:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29913/abstract/52\">",
"      Zerres K, M&uuml;cher G, Becker J, et al. Prenatal diagnosis of autosomal recessive polycystic kidney disease (ARPKD): molecular genetics, clinical experience, and fetal morphology. Am J Med Genet 1998; 76:137.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6138 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-FF084CEA57-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_13_29913=[""].join("\n");
var outline_f29_13_29913=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H172118685\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88678601\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88678691\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88679525\">",
"      Genotype and phenotype correlation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88679753\">",
"      Kidney",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88679760\">",
"      Liver",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H139229729\">",
"      Renal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H139229722\">",
"      - Renal function impairment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25823482\">",
"      - Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Liver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88680812\">",
"      Lung",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88680828\">",
"      Potter syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88680906\">",
"      Other findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88680805\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88680962\">",
"      - Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H172118662\">",
"      Renal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H172118669\">",
"      Hepatic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172118577\">",
"      - Other modalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172118677\">",
"      Molecular genetic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172118597\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88680568\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H521057287\">",
"      Neonatal respiratory distress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25823552\">",
"      Other supportive measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25823736\">",
"      Renal status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25823743\">",
"      - Renal replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25823890\">",
"      Hepatic status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25823639\">",
"      Potential complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25823715\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25824024\">",
"      Counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25824243\">",
"      Future potential therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172118685\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6138\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6138|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/44/3783\" title=\"picture 1\">",
"      Histopathology of ARPKD kidney",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/28/27076\" title=\"picture 2\">",
"      Cross section ARPKD kidney",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/12/22721\" title=\"picture 3\">",
"      Potters syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27674?source=related_link\">",
"      Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28584?source=related_link\">",
"      Autosomal dominant polycystic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2902?source=related_link\">",
"      Caroli disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=related_link\">",
"      Course and treatment of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=related_link\">",
"      Extrarenal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27591?source=related_link\">",
"      Fluid and electrolyte therapy in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34009?source=related_link\">",
"      Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30582?source=related_link\">",
"      Hypertension in autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=related_link\">",
"      Maintenance fluid therapy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42936?source=related_link\">",
"      Management of hypertension in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14233?source=related_link\">",
"      Oligohydramnios",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=related_link\">",
"      Preimplantation genetic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2712?source=related_link\">",
"      Renal cystic diseases in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43303?source=related_link\">",
"      Renal manifestations of tuberous sclerosis and renal angiomyolipoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30824?source=related_link\">",
"      Statins and chronic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_13_29914="Treatment of candidemia and invasive candidiasis in adults";
var content_f29_13_29914=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of candidemia and invasive candidiasis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/13/29914/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/13/29914/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/13/29914/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/13/29914/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/13/29914/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/13/29914/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/13/29914/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term candidemia describes the presence of Candida species in the blood. Candidemia is the most common manifestations of invasive candidiasis. Candida in a blood culture should never be viewed as a contaminant and should always prompt a search for the source of the bloodstream infection. For many patients, candidemia is a manifestation of invasive candidiasis that could have originated in a variety of organs, whereas for others, candidemia originated from an infected indwelling intravenous catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In all cases, candidemia requires treatment with an antifungal agent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/2\">",
"     2",
"    </a>",
"    ]; it should never be assumed that removal of a catheter alone is adequate therapy for candidemia. Several studies have noted the high mortality rates associated with candidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/3-5\">",
"     3-5",
"    </a>",
"    ] and have shown that mortality is highest in those patients who were not treated with an antifungal drug [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Furthermore, prompt initiation of therapy is crucial.",
"   </p>",
"   <p>",
"    The treatment of candidemia in adults will be reviewed here. The epidemiology, pathogenesis, clinical manifestations, and diagnosis of candidemia are discussed separately; an overview of Candida infections and the management of other forms of invasive candidiasis are also presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=see_link\">",
"     \"Epidemiology and pathogenesis of candidemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=see_link\">",
"     \"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42071?source=see_link\">",
"     \"Overview of Candida infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40566?source=see_link\">",
"     \"Candida endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10071?source=see_link\">",
"     \"Hepatosplenic candidiasis (chronic disseminated candidiasis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39559?source=see_link\">",
"     \"Candida infections of the central nervous system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11671?source=see_link\">",
"     \"Candida osteoarticular infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of candidemia in neonates and children is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40760?source=see_link\">",
"     \"Treatment of Candida infection in neonates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3336?source=see_link\">",
"     \"Treatment of candidemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antifungal susceptibility testing is also reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/21/29018?source=see_link\">",
"     \"Antifungal susceptibility testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H331738097\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. albicans is the most common cause of candidemia, but there has been increased isolation of non-albicans species of Candida in recent years. Most prominent have been C. glabrata and C. parapsilosis, followed by C. tropicalis and C. krusei. This is important because some C. glabrata isolates are resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    , and all C. krusei isolates are resistant to fluconazole (",
"    <a class=\"graphic graphic_table graphicRef61023 \" href=\"UTD.htm?37/33/38428\">",
"     table 1",
"    </a>",
"    ). In addition, the minimal inhibitory concentrations for C. parapsilosis with all the echinocandins are higher than for other Candida species. Risk factors for infection with fluconazole-resistant Candida species include neutropenia, recent azole use, and others. The epidemiology of candidemia is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology and pathogenesis of candidemia in adults\", section on 'Prevalence of Candida species'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTIFUNGAL AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic antifungal classes for the treatment of candidiasis include the polyenes, azoles, and echinocandins. The relative advantages and disadvantages of available agents are discussed in this section. Efficacy is discussed below. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Azoles'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H16\">",
"     'Echinocandins'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H230583038\">",
"     'Amphotericin B'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Azoles",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    has been widely used for the treatment of candidiasis since its approval by the United States Food and Drug Administration (FDA) in 1990. The azoles work primarily by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-alpha-demethylase [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/6\">",
"     6",
"    </a>",
"    ]. This enzyme is necessary for the conversion of lanosterol to ergosterol, a vital component of the cellular membrane of fungi. General susceptibility patterns of Candida species to fluconazole and other antifungal agents are shown in the Table (",
"    <a class=\"graphic graphic_table graphicRef61023 \" href=\"UTD.htm?37/33/38428\">",
"     table 1",
"    </a>",
"    ). Some laboratories only screen C. glabrata isolates for susceptibility to fluconazole because this species has varying susceptibility. Antifungal susceptibility testing is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/21/29018?source=see_link\">",
"     \"Antifungal susceptibility testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    has an excellent safety profile and is available in intravenous and oral formulations and is also inexpensive, since it is now generic. Fluconazole is highly bioavailable, making oral dosing appropriate for most patients. Most trials evaluating the efficacy of fluconazole for candidemia have used 400 or 800 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. For candidemia, we recommend that fluconazole be dosed as follows: 800 mg (12",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    loading dose, then 400 mg (6",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    orally daily [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other available azoles include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The activity of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      against Candida species is superior to that of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      , with minimal inhibitory concentrations that are a log or more less than fluconazole [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/11\">",
"       11",
"      </a>",
"      ]. However, cross-resistance between fluconazole and voriconazole is seen frequently, especially with C. glabrata. Voriconazole has significantly greater in vitro activity against C. krusei isolates compared with fluconazole, because of more effective binding of its cytochrome P450 isoenzyme [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/21/29018?source=see_link&amp;anchor=H27#H27\">",
"       \"Antifungal susceptibility testing\", section on 'Azoles'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/21/29018?source=see_link&amp;anchor=H34#H34\">",
"       \"Antifungal susceptibility testing\", section on 'Azoles'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       Posaconazole",
"      </a>",
"      is available only as an oral suspension. It is approved for use as a prophylactic agent for fungal infections in allogeneic hematopoietic cell transplant recipients with graft-versus-host disease and in patients with prolonged neutropenia due to chemotherapy for hematologic malignancies. It is also approved for oropharyngeal candidiasis, but not for systemic candidiasis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=see_link\">",
"       \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link\">",
"       \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20793?source=see_link\">",
"       \"Treatment of oropharyngeal and esophageal candidiasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      is sometimes used for mucosal candidiasis, but is",
"      <strong>",
"       not",
"      </strong>",
"      used for systemic infections.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Azoles interact with multiple different cytochrome P450 enzymes; alternative antifungal agents, such as echinocandins, may be preferred if patients are taking other medications that utilize P450 pathways. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H31#H31\">",
"     \"Pharmacology of azoles\", section on 'Drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pharmacology of the azoles is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Echinocandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The echinocandins include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    . Echinocandins are noncompetitive inhibitors of the synthesis of 1,3-beta-D-glucan, which is an integral component of the fungal cell wall [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/13\">",
"     13",
"    </a>",
"    ]. They have excellent activity against most Candida species, have favorable toxicity profiles, and are approved for the treatment of candidemia and other forms of invasive candidiasis. The echinocandins are preferred over azoles for the initial treatment of candidemia if C. glabrata or C. krusei is identified or suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to their broad-spectrum activity against Candida species, the echinocandins are used extensively for candidemia and invasive candidiasis. The highest echinocandin MICs are found for C. parapsilosis and C. guilliermondii. Resistance to echinocandins has been noted in only a few individual cases until recently. However, acquired resistance has been increasingly reported, especially in C. glabrata. The mechanism of echinocandin resistance is similar in all species and involves mutations in the FKS 1 or FKS 2 genes that control the enzyme targeted by the echinocandins.",
"   </p>",
"   <p>",
"    The echinocandins do not have activity against Cryptococcus or Trichosporon species [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The echinocandins are administered intravenously as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       Caspofungin",
"      </a>",
"      is given at an initial dose of 70 mg on the first day of treatment, followed by 50 mg daily; dose reduction is required with hepatic dysfunction.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"       Anidulafungin",
"      </a>",
"      is given at an initial dose of 200 mg on the first day, followed by 100 mg daily.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       Micafungin",
"      </a>",
"      is given at a dose of 100 mg daily for candidemia; no loading dose is needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adverse effects of all echinocandins are generally mild and include fever, thrombophlebitis, headache, and elevated aminotransferases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/14\">",
"     14",
"    </a>",
"    ]. The pharmacology of the echinocandins is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9338?source=see_link\">",
"     \"Pharmacology of echinocandins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H230582206\">",
"    <span class=\"h2\">",
"     Amphotericin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    is a polyene antifungal agent that disrupts fungal cell wall synthesis because of its ability to bind to sterols, primarily ergosterol, which leads to the formation of pores that allow leakage of cellular components. Amphotericin B deoxycholate, which was the standard drug for the treatment of candidiasis for decades, demonstrates rapidly cidal in vitro activity against most species of Candida. It is also associated with significant nephrotoxicity. This has led to the development of various lipid-based derivatives, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"     amphotericin B lipid complex",
"    </a>",
"    (ABLC). A third formulation, amphotericin B colloidal dispersion (ABCD) is used infrequently, in part because it causes more infusion-related reactions than amphotericin B deoxycholate. These lipid-based compounds have much less toxicity than amphotericin deoxycholate but are significantly more expensive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=see_link\">",
"     \"Pharmacology of amphotericin B\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=see_link\">",
"     \"Amphotericin B nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommended doses for candidemia follow [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lipid formulations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      &mdash; 3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       Amphotericin B",
"      </a>",
"      deoxycholate &mdash; 0.5 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUSCEPTIBILITY PATTERNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Susceptibility testing for Candida species is becoming more readily available and widely used. General susceptibility patterns are shown in the Table (",
"    <a class=\"graphic graphic_table graphicRef61023 \" href=\"UTD.htm?37/33/38428\">",
"     table 1",
"    </a>",
"    ), and general patterns for each class of antifungal agent are discussed above. (See",
"    <a class=\"local\" href=\"#H230582206\">",
"     'Amphotericin B'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Azoles'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'Echinocandins'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For most patients with invasive candidiasis, the most important issue is whether the isolate is susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    . Some laboratories only screen C. glabrata isolates for susceptibility to fluconazole because this species has varying susceptibility. Increasingly, resistance among C. glabrata isolates has been noted to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , as well as fluconazole.",
"   </p>",
"   <p>",
"    Specific drug resistance information for the various Candida species is found below. Antifungal susceptibility testing is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/21/29018?source=see_link\">",
"     \"Antifungal susceptibility testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     C. albicans",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of C. albicans resistance is extremely low. An analysis of in vitro susceptibilities of approximately 90,000 isolates of C. albicans collected from 40 countries from 1997 to 2005 demonstrated that only 1.5 percent were resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/15\">",
"     15",
"    </a>",
"    ]. Individual cases and small series of non-mucosal infection with fluconazole-resistant C. albicans have been reported from several tertiary care centers, and usually occur in immunosuppressed patients who are taking fluconazole chronically for prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most C. albicans isolates are susceptible to the echinocandins, although resistance has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The vast majority of C. albicans isolates are susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     C. krusei",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. krusei is intrinsically resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    due to an altered cytochrome P450 isoenzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/21\">",
"     21",
"    </a>",
"    ]. This resistance cannot be overcome with use of higher drug doses.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    binds more effectively to the cytochrome P450 isoenzyme in C. krusei than fluconazole, resulting in higher rates of susceptibility [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are geographic differences in the incidence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    resistance. In an international surveillance study that included nearly 3500 bloodstream isolates of C. krusei, 83 percent of isolates were susceptible to voriconazole, ranging from 75 percent in Latin America to 92 percent in North America [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/23\">",
"     23",
"    </a>",
"    ]. C. krusei isolates are usually susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the large surveillance study described above, all C. krusei isolates were susceptible to the echinocandins (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/23\">",
"     23",
"    </a>",
"    ]. However, individual cases of resistance to the echinocandins have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    C. krusei demonstrates decreased susceptibility to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , requiring higher doses (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily of amphotericin B deoxycholate or 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily of lipid-based formulations) to be used for treatment. C. krusei is usually resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     C. glabrata",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many C. glabrata isolates are resistant to the azoles, mostly due to changes in drug efflux [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/2,28\">",
"     2,28",
"    </a>",
"    ]. This type of resistance can sometimes be overcome by using higher doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    . Cross-resistance among the azoles is common with C. glabrata. Among the Candida species, the MICs for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    are highest with C. glabrata. Isolates that are resistant to fluconazole are generally resistant to voriconazole, as well [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The echinocandins have generally retained excellent activity against C. glabrata, although isolated cases of resistance have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/31-35\">",
"     31-35",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Of note, there is increasing concern that some C. glabrata bloodstream isolates with resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    are also resistant to the echinocandins. In a surveillance study of the in vitro susceptibility of 1669 C. glabrata bloodstream isolates collected in the United States between 2006 and 2010, 162 isolates (9.7 percent) were resistant to fluconazole, of which 98.8 percent were also not susceptible to voriconazole and 9.3, 9.3, and 8.0 percent were resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    , respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/30\">",
"     30",
"    </a>",
"    ]. Of the 162 isolates that were resistant to fluconazole, 18 (11.1 percent) were resistant to one or more of the echinocandins; all of these isolates contained an FKS1 or FKS2 mutation. In comparison, there were no echinocandin-resistant strains detected among 110 fluconazole-resistant C. glabrata isolates tested between 2001 and 2004, years in which echinocandins were used sparingly. It is not clear what impact these findings will have on treatment regimens for candidemia.",
"   </p>",
"   <p>",
"    <br/>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    has delayed killing kinetics against C. glabrata in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/36\">",
"     36",
"    </a>",
"    ]; higher doses of amphotericin B are recommended when treating known C. glabrata infection (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily of amphotericin B deoxycholate or 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily of lipid-based formulations).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     C. parapsilosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. parapsilosis is highly susceptible to most antifungal agents; however, the minimal inhibitory concentrations for C. parapsilosis with all the echinocandins are higher than for other Candida species [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/28\">",
"     28",
"    </a>",
"    ]. The clinical implications of these in vitro data are unclear. In the study that established the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    in the treatment of invasive candidiasis, five of nine patients with persistent candidemia were infected with C. parapsilosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/37\">",
"     37",
"    </a>",
"    ]. However, the overall response rate to caspofungin in these patients was the same as in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    comparator arm.",
"   </p>",
"   <p>",
"    In an analysis of five trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    use in patients with invasive candidiasis, the overall (clinical and microbiologic) success rate among patients with C. parapsilosis (74 percent) was similar to patients with invasive candidiasis caused by other Candida species [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An international surveillance study of 9371 C. parapsilosis isolates collected between 2001 and 2005 found the following [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High rates of susceptibility to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (91 to 96 percent) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (95 to 98 percent) were seen in all geographic regions except Africa and the Middle East (79 and 86 percent susceptible to fluconazole and voriconazole, respectively).",
"     </li>",
"     <li>",
"      Isolates from the surgical intensive care unit (ICU) were the least susceptible to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (86 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H230584204\">",
"    <span class=\"h2\">",
"     C. tropicalis",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. tropicalis is usually susceptible to the azoles,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , and the echinocandins. However, breakthrough C. tropicalis bloodstream infections with resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    have been reported rarely in patients with hematologic malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/20,40,41\">",
"     20,40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1392678\">",
"    <span class=\"h2\">",
"     C. lusitaniae",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. lusitaniae is unique among Candida species in that it is often resistant to or quickly becomes resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    ; however, it is usually susceptible to the azoles and echinocandins [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1392705\">",
"    <span class=\"h2\">",
"     C. guilliermondii",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. guilliermondii is an uncommon Candida species that in some studies has appeared to cause infections more often in patients who have hematologic malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/43\">",
"     43",
"    </a>",
"    ]. Treatment can be problematic because some isolates have reduced susceptibility to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    and many have reduced susceptibility to echinocandins [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/44\">",
"     44",
"    </a>",
"    ]. However, C. guilliermondii is usually susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1392759\">",
"    <span class=\"h2\">",
"     C. dubliniensis",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. dubliniensis shares many phenotypic traits with C. albicans, and many isolates were previously misidentified as C. albicans. Special techniques must be undertaken in the microbiology laboratory to differentiate between these two species [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/45\">",
"     45",
"    </a>",
"    ]. C. dubliniensis rose to importance in the mid-1990s when it was found primarily in AIDS patients and most of the isolates were",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    -resistant. It has subsequently been shown that this species causes disease in other populations as well, and the susceptibilities are similar to those of C. albicans. Most C. dubliniensis isolates are azole-susceptible and can therefore be treated with fluconazole; they are also susceptible to echinocandins and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H230580859\">",
"    <span class=\"h2\">",
"     Antifungal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common antifungal agents used currently for the treatment of candidemia are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    and the echinocandins (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    ). Formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    are given less often due to the risk of toxicity. Both the echinocandins and the azoles are better tolerated than amphotericin B formulations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several randomized trials have shown that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    is as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    for the treatment of candidemia in immunocompetent patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/7-9,47\">",
"     7-9,47",
"    </a>",
"    ]. The echinocandins appear to be as effective as and better tolerated than amphotericin B formulations and, in one study, more effective than fluconazole [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/37,48-50\">",
"     37,48-50",
"    </a>",
"    ]. The majority of patients in these studies were not neutropenic.",
"   </p>",
"   <p>",
"    Data are more limited in neutropenic patients with candidemia. No randomized trials have been adequately powered to evaluate the efficacy of antifungal therapy in neutropenic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/2\">",
"     2",
"    </a>",
"    ], and data are derived from small subset analyses of randomized trials, open-label studies, and retrospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/9,37,48,51-53\">",
"     9,37,48,51-53",
"    </a>",
"    ]. Based upon the widespread use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    prophylaxis in neutropenic patients and the resulting increased prevalence of non-albicans Candida species with reduced susceptibility to fluconazole, most neutropenic patients with candidemia are treated with an echinocandin or an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    formulation. (See",
"    <a class=\"local\" href=\"#H230581758\">",
"     'Neutropenic patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Azoles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several large randomized trials have shown that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    is as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    for the treatment of candidemia in immunocompetent patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/7-9,47\">",
"     7-9,47",
"    </a>",
"    ]. One study compared the two drugs in 206 patients, 75 percent of whom had intravenous catheters in place at the time of candidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/7\">",
"     7",
"    </a>",
"    ]. The two drugs achieved an equivalent overall success rate (72 versus 79 percent for fluconazole and amphotericin B, respectively). Nephrotoxicity was significantly less with fluconazole (2 versus 37 percent). Another study noted success rates of 57 percent for fluconazole and 62 percent for amphotericin B and confirmed the superior safety profile of fluconazole [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another randomized trial,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    was compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    for treatment of invasive candidiasis in 245 patients: 89 percent had candidemia and only 3 percent were neutropenic [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/49\">",
"     49",
"    </a>",
"    ]. The combined clinical and microbiologic response rates were significantly higher in patients assigned to the anidulafungin arm both at the end of therapy (74 versus 57 percent) and at two-week follow-up (65 versus 49 percent). Mortality rates at 60 days were similar.",
"   </p>",
"   <p>",
"    The effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    for candidemia was shown in a randomized trial in non-neutropenic patients who were treated with either voriconazole alone or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    for three to seven days followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/54\">",
"     54",
"    </a>",
"    ]. Voriconazole therapy led to sterilization of the bloodstream as rapidly as sequential therapy. Success rates at the end of treatment (66 percent for voriconazole and 71 percent for sequential therapy) were similar to those noted in previous trials with other antifungal regimens for the treatment of candidemia. The clinical and mycological response at 12 weeks (the primary endpoint of this study) demonstrated 41 percent efficacy in both groups. Use of a 12 week primary end point led to unusually low overall responses rates for both regimens, reflecting the serious underlying illnesses seen in patients with candidemia, rather than drug failure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical role for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    in comparison with echinocandins remains unclear. A major concern is the cross-resistance to voriconazole that is seen among many isolates of C. glabrata that are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    -resistant. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'C. glabrata'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H19\">",
"     'C. glabrata and C. krusei'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Echinocandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several randomized trials have compared the efficacy of echinocandins to either an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    formulation or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    among patients with invasive candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/37,48-50\">",
"     37,48-50",
"    </a>",
"    ]. The majority of patients had candidemia and were not neutropenic.",
"   </p>",
"   <p>",
"    The echinocandins appear to be as effective as and better tolerated than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    formulations and, in one study, more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one randomized trial,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       caspofungin",
"      </a>",
"      was shown to be equivalent in efficacy to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/37\">",
"       37",
"      </a>",
"      ]. Patients were randomly assigned to the two different treatment arms controlling for neutropenia and APACHE II scores. In an analysis that excluded patients who did not have a documented infection or received less than one day of the treatment drug, the two drugs demonstrated equivalent efficacy (73 percent for caspofungin versus 62 percent for amphotericin B). Caspofungin was associated with less toxicity.",
"     </li>",
"     <li>",
"      A randomized multinational non-inferiority trial compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       micafungin",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/48\">",
"       48",
"      </a>",
"      ]. In a modified intent-to-treat analysis, success rates for clinical and microbiologic cure were similar (74 and 70 percent for micafungin and liposomal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      , respectively). Micafungin was associated with fewer adverse events. In a later subset analysis of only those patients who had infection with C. glabrata or C. krusei, outcomes were similar between those receiving micafungin and those receiving liposomal amphotericin B [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another randomized trial,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"       anidulafungin",
"      </a>",
"      resulted in superior combined clinical and microbiologic response compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (65 versus 49 percent at two-week follow-up), although 60-day mortality rates were similar, as discussed above [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/49\">",
"       49",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Azoles'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data are more limited in neutropenic patients with candidemia compared with non-neutropenic patients. Efficacy data for the echinocandins in neutropenic patients comes from small subset analyses of randomized trials and open-label studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/37,48,51,52\">",
"     37,48,51,52",
"    </a>",
"    ]. Although the efficacy of the echinocandins in neutropenic patients cannot be firmly established based upon these studies, the response rates to the echinocandins appear to be similar to or better than formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    A separate issue is the relative efficacy of the different echinocandins. This was addressed in a randomized trial of adults with candidemia and other forms of invasive candidiasis that compared two doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    (100 mg or 150 mg daily) to one another and to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    (70 mg once followed by 50 mg daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/51\">",
"     51",
"    </a>",
"    ]. The lower dose of micafungin was equivalent to both the higher dose of micafungin and to caspofungin.",
"   </p>",
"   <p>",
"    In a later subset analysis of only those patients who had infection with C. glabrata or C. krusei, outcomes were similar among the three treatment groups [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/50\">",
"     50",
"    </a>",
"    ]. In another trial, two different doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    (70 mg once followed by 50 mg daily versus 150 mg daily) were compared in patients being treated for invasive candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/56\">",
"     56",
"    </a>",
"    ]. Similar rates of mortality (at eight weeks) and significant adverse effects were observed between the groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H230583038\">",
"    <span class=\"h3\">",
"     Amphotericin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    formulations have been proven to be effective in several randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/7-9,47\">",
"     7-9,47",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Azoles'",
"    </a>",
"    above). However, amphotericin B formulations are often avoided due to their increased toxicity compared with azoles and echinocandins. They remain useful in cases when resistance to the other antifungal classes is suspected or proven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H883985359\">",
"    <span class=\"h3\">",
"     Comparison of trial data",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2008 meta-analysis of 15 randomized trials compared different antifungal agents for the treatment of invasive candidiasis and found that there were no differences in mortality between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    or the echinocandins [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/46\">",
"     46",
"    </a>",
"    ]. However, there was a higher rate of microbiologic failure in patients who received fluconazole compared with amphotericin B (RR 1.52; 95% CI 1.12-2.07) or the echinocandin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    (RR 2.0; 95% CI 1.16-3.44).",
"   </p>",
"   <p>",
"    A 2012 patient-level quantitative review evaluated observational data gathered from 1915 patients included in seven randomized treatment trials of candidemia and invasive candidiasis, including those described above [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/57\">",
"     57",
"    </a>",
"    ]. Patients who were treated with an echinocandin had improved survival compared with those treated with an azole or an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    formulation (odds ratio 0.65, 95% CI 0.45-0.94).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Choice of initial antifungal agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;When choosing an antifungal agent in patients with suspected candidemia, the following factors should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of recent azole exposure",
"     </li>",
"     <li>",
"      Prevalence of different Candida species and current antifungal susceptibility data in the clinical unit and medical center",
"     </li>",
"     <li>",
"      Severity of illness",
"     </li>",
"     <li>",
"      Relevant comorbidities that increase the risk of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      -resistant Candida species (eg, neutropenia) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=see_link\">",
"       \"Epidemiology and pathogenesis of candidemia in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Evidence of involvement of the central nervous system, cardiac valves, eyes,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      visceral organs",
"     </li>",
"     <li>",
"      History of intolerance of to an antifungal agent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is particularly important to determine the risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    -resistant Candida isolates, such as C. glabrata and C. krusei (see",
"    <a class=\"local\" href=\"#H19\">",
"     'C. glabrata and C. krusei'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H230581751\">",
"    <span class=\"h4\">",
"     Non-neutropenic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In non-neutropenic patients with candidemia who are clinically stable, who have not been exposed to recent azole therapy, and who are in clinical units or medical centers in which C. glabrata or C. krusei are uncommonly isolated (&lt;15 percent of all species causing candidemia), we suggest initial therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    rather than an echinocandin (",
"    <a class=\"graphic graphic_table graphicRef87676 \" href=\"UTD.htm?9/28/9677\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Azoles'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In non-neutropenic patients with moderately severe or severe infections",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    who are at increased risk of C. glabrata or C. krusei infection, we favor an echinocandin (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    ) and we would",
"    <strong>",
"     not",
"    </strong>",
"    use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    as initial therapy, prior to the identification of the causative species [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/2\">",
"     2",
"    </a>",
"    ]. However, in patients who have documented C. glabrata infection, who are already improving clinically on fluconazole or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , and whose follow-up blood cultures are negative, continuing with the azole is reasonable. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'C. glabrata and C. krusei'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H5\">",
"     'Echinocandins'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H230581758\">",
"    <span class=\"h4\">",
"     Neutropenic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who are neutropenic, there are several important considerations in choosing appropriate therapy for candidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most neutropenic patients with candidemia should be treated with an echinocandin or an",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      formulation since neutropenic patients are at increased risk for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      -resistant Candida spp, such as C. glabrata and C. krusei, especially if they have recently received azole prophylaxis (",
"      <a class=\"graphic graphic_table graphicRef87676 \" href=\"UTD.htm?9/28/9677\">",
"       table 2",
"      </a>",
"      ). If amphotericin B is used, a lipid formulation is preferred. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'C. glabrata and C. krusei'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H5\">",
"       'Echinocandins'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H230582206\">",
"       'Amphotericin B'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       Fluconazole",
"      </a>",
"      should be restricted to clinically stable patients who have not received recent azole prophylaxis. (See",
"      <a class=\"local\" href=\"#H230582206\">",
"       'Amphotericin B'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Azoles'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Echinocandins'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H323853372\">",
"    <span class=\"h4\">",
"     C. parapsilosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with candidemia caused by C. parapsilosis should be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    rather than an echinocandin [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/2\">",
"     2",
"    </a>",
"    ]. However, for patients with C. parapsilosis who are already improving clinically on an echinocandin and whose follow-up blood cultures are negative, continuing with the echinocandin is reasonable. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'C. parapsilosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h4\">",
"     C. glabrata and C. krusei",
"    </span>",
"    &nbsp;&mdash;&nbsp;A difficult issue is which antifungal agent to use when C. glabrata is isolated from the blood [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/2\">",
"     2",
"    </a>",
"    ]. Because many C. glabrata strains are resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    , the most conservative approach is to treat fungemia due to this species with an agent other than fluconazole. However, several studies that used fluconazole found no differences in outcome related to the species causing candidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/7,58,59\">",
"     7,58,59",
"    </a>",
"    ]. In a study in cancer patients, C. glabrata bloodstream infection responded less well to therapy than C. albicans, but neither the initial regimen nor the species of Candida was an independent predictor of poor outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/60\">",
"     60",
"    </a>",
"    ]. Nevertheless, based on in vitro data, it is still prudent to avoid use of fluconazole for treatment of C. glabrata. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'C. glabrata'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Since C. krusei is intrinsically resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    , this agent is avoided when C. krusei is suspected. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'C. krusei'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Because of its safety profile, an echinocandin is now preferred over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    for treatment of candidemia due to C. glabrata and C. krusei.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is also approved for this indication, but there is likely to be cross-resistance between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    and voriconazole among C. glabrata isolates. This cross-resistance does",
"    <strong>",
"     not",
"    </strong>",
"    occur with C. krusei. In clinical units or medical centers in which C. glabrata or C. krusei are commonly isolated (defined as &gt;15 percent of all species causing candidemia), we suggest using an echinocandin rather than fluconazole for empiric therapy until the species is known. There are few differences among the echinocandins, and any of the three approved agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    ) can be used. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Echinocandins'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    An",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    formulation may be used as an alternative agent for C. glabrata or C. krusei infection when necessary. In patients with C. glabrata or C. krusei infections being treated with amphotericin B, higher doses of amphotericin B are recommended (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily of amphotericin B deoxycholate or 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily of lipid-based formulations), particularly in immunocompromised hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/2,28\">",
"     2,28",
"    </a>",
"    ]. We prefer lipid formulations of amphotericin B to amphotericin B deoxycholate because the lipid formulations have fewer toxicities. (See",
"    <a class=\"local\" href=\"#H230582206\">",
"     'Amphotericin B'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H323853594\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    , the echinocandins, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    formulations is discussed above. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Azoles'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'Echinocandins'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H230582206\">",
"     'Amphotericin B'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H230581818\">",
"    <span class=\"h3\">",
"     Oral step-down therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Candida isolates likely to be susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (eg, C. albicans) who are clinically stable can be switched from an echinocandin to fluconazole [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is recommended as oral step-down therapy only for patients with C. krusei or voriconazole-susceptible C. glabrata [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/2\">",
"     2",
"    </a>",
"    ]. For other Candida isolates, it does not offer a clear advantage compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H230581125\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appropriate duration of therapy for candidemia has not been studied. A minimum of two weeks of therapy after blood cultures become negative has been used in most clinical trials, and is the recommended duration in the 2009 Infectious Diseases Society of America (IDSA) guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/2\">",
"     2",
"    </a>",
"    ]. Daily blood cultures should be performed after initiating therapy in order to determine the date of sterilization. If blood cultures remain positive, then a search for a metastatic focus, such as an abscess or endocarditis, must be undertaken. In addition, all patients should have resolution of symptoms attributable to candidemia",
"    <strong>",
"     and",
"    </strong>",
"    resolution of neutropenia before antifungal therapy is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A longer duration of therapy and consultation with an infectious disease specialist are warranted in patients who have metastatic foci of infection or endocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39112?source=see_link\">",
"     \"Treatment of endogenous endophthalmitis due to Candida species\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11671?source=see_link\">",
"     \"Candida osteoarticular infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40566?source=see_link\">",
"     \"Candida endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10071?source=see_link\">",
"     \"Hepatosplenic candidiasis (chronic disseminated candidiasis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H230581214\">",
"    <span class=\"h3\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether more than one antifungal agent should be used together for the treatment of candidemia has not been established, although combination therapy is",
"    <strong>",
"     not",
"    </strong>",
"    generally given for the treatment of candidemia.",
"   </p>",
"   <p>",
"    A controlled trial randomly assigned 219 non-neutropenic patients with candidemia to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (800",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    alone for two weeks or fluconazole (800",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (0.7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) for the first four to seven days followed by fluconazole alone to finish the two week course [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/10\">",
"     10",
"    </a>",
"    ]. There was more rapid clearing of fungemia with initial combination therapy, but the success rates overall were similar in the two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Ophthalmologic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients who have candidemia should undergo an ophthalmologic examination by an ophthalmologist to look for evidence of endophthalmitis, whether or not they have ocular symptoms, as recommended in the IDSA guidelines for treatment of candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13849?source=see_link&amp;anchor=H79280403#H79280403\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis\", section on 'Ophthalmic examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Catheter removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central intravenous catheters should be removed in patients with candidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/2,61\">",
"     2,61",
"    </a>",
"    ]. Clearance of fungemia occurs more quickly when catheters are removed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/62,63\">",
"     62,63",
"    </a>",
"    ], and higher mortality has been documented if catheters remain [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/4,57,63-65\">",
"     4,57,63-65",
"    </a>",
"    ]. In addition, treatment with an antifungal agent is required [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/2\">",
"     2",
"    </a>",
"    ]; it should never be assumed that removal of a catheter alone is adequate therapy for candidemia.",
"   </p>",
"   <p>",
"    Some authorities have suggested that catheter removal may not be necessary in neutropenic patients with candidemia (eg, patients with hematologic malignancies undergoing cytotoxic chemotherapy, hematopoietic cell transplant recipients), in whom the source is often the gastrointestinal tract rather than the central venous catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Some clinicians will attempt to retain the catheters in such patients. A case can be made for the gastrointestinal tract as the source of candidemia in many patients, especially those who are neutropenic or who have disruption of gastrointestinal tract integrity due to graft-versus-host disease or chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. An extension of this argument, put forth by the same authors, is that not all catheters have to be removed in non-neutropenic patients with candidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies, albeit with limitations, have evaluated whether central venous catheter removal is beneficial:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective subgroup analysis of two randomized trials of patients with candidemia was performed in order to assess the potential benefit of early central venous catheter removal [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/67\">",
"       67",
"      </a>",
"      ]. In the univariate analysis, early removal of the central venous catheter (within 24 or 48 hours) did not improve time to mycologic eradication or rates of persistent of recurrent candidemia, but was associated with improved treatment success and survival. However, in the multivariate analysis, these benefits were lost.",
"     </li>",
"     <li>",
"      A study in cancer patients used a fivefold difference in quantitative cultures taken from the central catheter and a peripheral vein to help define catheter-associated candidemia [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/70\">",
"       70",
"      </a>",
"      ]. Using these criteria, patients with non-catheter sources did not benefit from catheter removal in addition to antifungal agents.",
"     </li>",
"     <li>",
"      In contrast to the studies described above, an individual patient-level quantitative review that evaluated observational data gathered from seven randomized treatment trials of candidemia and invasive candidiasis found that removal of a central venous catheter was associated with decreased mortality (odds ratio 0.50, 95% CI 0.35-0.72) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are multiple limitations to observational studies and subgroup analyses of randomized trials, including unrecognized confounders, treatment bias, lack of standardized criteria for catheter removal or data on time to removal, and lack of statistical power [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Despite the controversy, the current consensus, including that noted by the IDSA guidelines, remains that in most patients with candidemia, intravascular catheters should be removed, realizing that in some patients this may not be feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/2,61-63,71,73\">",
"     2,61-63,71,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H230581572\">",
"    <span class=\"h1\">",
"     EMPIRIC ANTIFUNGAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric antifungal therapy is given routinely to patients with neutropenic fever since they are at substantial risk for invasive candidiasis. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link&amp;anchor=H154974350#H154974350\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\", section on 'Addition of an antifungal agent'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, non-neutropenic patients who have persistent fever or unexplained hypotension despite broad-spectrum antibacterial agents may have candidemia or invasive candidiasis. These patients may benefit from early empiric or pre-emptive therapy with an antifungal agent. The choice of agent should be guided by the hemodynamic stability of the patient and with whether the patient has a history of prior exposure to antifungal agents [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/74\">",
"     74",
"    </a>",
"    ]. If the etiologic agent has not been identified, the approach to empiric therapy will be influenced by whether the patient is known to be colonized with resistant Candida species and the proportion of candidemias due to resistant species within a particular medical center or patient unit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology and pathogenesis of candidemia in adults\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2009 Infectious Diseases Society of America (IDSA) guidelines recommend that empiric antifungal therapy should be considered in critically ill patients who are at risk for invasive candidiasis and who have persistent fevers despite antibacterial therapy (",
"    <a class=\"graphic graphic_table graphicRef87676 \" href=\"UTD.htm?9/28/9677\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/2\">",
"     2",
"    </a>",
"    ]. Criteria for the need for empiric therapy remain poorly defined and should include the clinical assessment of risk factors (eg, central venous catheters,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    , hemodialysis, trauma, broad-spectrum antibiotics, recent surgery [particularly abdominal surgery]), serologic markers for invasive candidiasis (eg, beta-D-glucan), if available, and culture data regarding Candida colonization at non-sterile sites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology and pathogenesis of candidemia in adults\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is not clear whether the empiric use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    is beneficial. One multicenter randomized trial in the intensive care unit (ICU) setting found no difference in rate of invasive candidiasis or outcomes between patients given fluconazole empirically and those given placebo; invasive candidiasis occurred in only nine patients in the fluconazole group and in 11 patients in the placebo group (5 versus 9 percent), a nonsignificant difference [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/75\">",
"     75",
"    </a>",
"    ]. However, this trial was underpowered, with so few patients developing invasive candidiasis that a significant treatment benefit could not be shown.",
"   </p>",
"   <p>",
"    We emphasize that empiric antifungal therapy should be given",
"    <strong>",
"     only",
"    </strong>",
"    to patients who are thought to be at substantial risk of invasive candidiasis. In such patients, we favor therapy with either an echinocandin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    , depending upon the risk of resistant Candida species. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology and pathogenesis of candidemia in adults\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H17\">",
"     'Choice of initial antifungal agent'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H230580774\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Untreated candidemia has a mortality rate of over 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/3\">",
"     3",
"    </a>",
"    ]. With treatment, the overall mortality of candidemia is approximately 30 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/57,72\">",
"     57,72",
"    </a>",
"    ]. A delay in treatment can increase mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. In one retrospective cohort study of 230 patients with candidemia, the number of days that passed from notification of the first positive culture for yeast to the initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    correlated with increased mortality rates as follows: day 0 (15 percent); day 1 (24 percent); day 2 (37 percent); day 3 (41 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among candidemic patients with septic shock, the outcomes are even poorer. In a retrospective cohort study of hospitalized patients with septic shock and a positive blood culture for Candida spp, 155 of 224 patients (64 percent) died during hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/79\">",
"     79",
"    </a>",
"    ]. The in-hospital mortality rate among the 142 patients who had adequate source control within 24 hours of the onset of septic shock and antifungal therapy administered within 24 hours of the onset of septic shock was 53 percent, compared with 98 percent among the 82 patients for whom these goals were not attained. On multivariate analysis, both failure to achieve timely source control (adjusted odds ratio [aOR] 77.4, 95% CI 21.5-278.4) and delayed antifungal therapy (aOR 33.8, 95% CI 9.7-118.0) were highly associated with in-hospital mortality. Other factors that were independently associated with in-hospital mortality on multivariate analysis included red blood cell transfusion, solid tumor with metastases, class IV congestive heart failure, and higher APACHE II score.",
"   </p>",
"   <p>",
"    Factors that have been associated with increased mortality in other studies of hospitalized patients with candidemia include higher APACHE II scores, inadequate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    dosing, retention of a central venous catheter, increasing age, use of immunosuppressive therapy, and infection with C. tropicalis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/57,64,80\">",
"     57,64,80",
"    </a>",
"    ]. C. parapsilosis has been associated with lower mortality rates than other Candida species [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/57\">",
"     57",
"    </a>",
"    ]. In ICU patients, diabetes mellitus, immunosuppression, and mechanical ventilation were associated with death in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/81\">",
"     81",
"    </a>",
"    ], whereas in non-ICU patients, glucocorticoid use at the time that a positive blood culture was drawn was associated with increased mortality in another study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among cancer patients, persistent neutropenia, higher APACHE III score, and visceral dissemination have been associated with poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/13/29914/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The choice of antifungal therapy for invasive candidiasis, including candidemia, depends upon a variety of factors including history of recent azole exposure; prevalence of different Candida species and current antifungal susceptibility data in the clinical unit and medical center; severity of illness; relevant comorbidities (eg, neutropenia, recent abdominal surgery); evidence of involvement of the central nervous system, cardiac valves, eyes,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      visceral organs; and history of intolerance to an antifungal agent. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Choice of initial antifungal agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For non-neutropenic patients with candidemia who are clinically stable, have not been exposed to recent azole therapy, and who are in clinical units or medical centers in which C. glabrata or C. krusei are uncommonly isolated (&lt;15 percent of all species causing candidemia), we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      rather than an echinocandin (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We also suggest fluconazole for the uncommon neutropenic patients who meet these criteria (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The usual dose of fluconazole is an 800 mg loading dose followed by 400 mg orally daily. (See",
"      <a class=\"local\" href=\"#H230581751\">",
"       'Non-neutropenic patients'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H230581758\">",
"       'Neutropenic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For non-neutropenic and neutropenic patients with candidemia who are clinically unstable, have received prior azole therapy, or are in institutions in which C. glabrata or C. krusei are common isolates, we suggest an echinocandin (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       caspofungin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       micafungin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"       anidulafungin",
"      </a>",
"      ) rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      for initial therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Treatment can be changed to fluconazole if a fluconazole-susceptible Candida species is identified. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'C. glabrata and C. krusei'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Choice of initial antifungal agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The echinocandins are administered intravenously as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       Caspofungin",
"      </a>",
"      is given at an initial dose of 70 mg on the first day of treatment, followed by 50 mg daily; dose reduction is required with hepatic dysfunction.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"       Anidulafungin",
"      </a>",
"      is given at an initial dose of 200 mg on the first day, followed by 100 mg daily.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       Micafungin",
"      </a>",
"      is given at a dose of 100 mg daily for candidemia; no loading dose is needed. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Echinocandins'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood cultures should be checked daily after initiating antifungal therapy until they become negative. (See",
"      <a class=\"local\" href=\"#H230581125\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients who have candidemia should undergo an ophthalmologic examination by an ophthalmologist to look for evidence of endophthalmitis, whether or not they have ocular symptoms. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Ophthalmologic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the patient with candidemia alone, treatment should be continued for 14 days after blood cultures have yielded no yeast. In addition, all patients should have resolution of symptoms attributable to candidemia",
"      <strong>",
"       and",
"      </strong>",
"      resolution of neutropenia before antifungal therapy is discontinued. Patients with candidemia and metastatic foci of infection (eg, eye, bone, heart, liver, spleen) require a longer duration of therapy. (See",
"      <a class=\"local\" href=\"#H230581125\">",
"       'Duration'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39112?source=see_link\">",
"       \"Treatment of endogenous endophthalmitis due to Candida species\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11671?source=see_link\">",
"       \"Candida osteoarticular infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40566?source=see_link\">",
"       \"Candida endocarditis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10071?source=see_link\">",
"       \"Hepatosplenic candidiasis (chronic disseminated candidiasis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Central intravenous catheters should be removed in patients with candidemia, when feasible. However, catheter removal is controversial in neutropenic patients, in whom the gastrointestinal tract is often the source. Some clinicians will attempt to retain the catheter in these patients. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Catheter removal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Empiric antifungal therapy recommendations in patients with neutropenic fever are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link&amp;anchor=H154974350#H154974350\">",
"       \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\", section on 'Addition of an antifungal agent'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest",
"      <strong>",
"       not",
"      </strong>",
"      giving empiric antifungal therapy to most patients in the intensive care unit (ICU) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, this approach, using either an echinocandin or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      , is reasonable in a subset of high-risk ICU patients who have",
"      <strong>",
"       all",
"      </strong>",
"      of the following characteristics:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Persistent fever despite broad-spectrum antibiotics",
"     </li>",
"     <li>",
"      Risk factors for invasive candidiasis",
"     </li>",
"     <li>",
"      Positive serologic markers for invasive candidiasis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      isolation of Candida from multiple non-sterile sites (see",
"      <a class=\"local\" href=\"#H230581572\">",
"       'Empiric antifungal therapy'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/1\">",
"      Fridkin SK. The changing face of fungal infections in health care settings. Clin Infect Dis 2005; 41:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/2\">",
"      Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/3\">",
"      Fraser VJ, Jones M, Dunkel J, et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/4\">",
"      Nguyen MH, Peacock JE Jr, Tanner DC, et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995; 155:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/5\">",
"      Nucci M, Colombo AL, Silveira F, et al. Risk factors for death in patients with candidemia. Infect Control Hosp Epidemiol 1998; 19:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/6\">",
"      Zonios DI, Bennett JE. Update on azole antifungals. Semin Respir Crit Care Med 2008; 29:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/7\">",
"      Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994; 331:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/8\">",
"      Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997; 16:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/9\">",
"      Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996; 23:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/10\">",
"      Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/11\">",
"      Cuenca-Estrella M, Rodriguez D, Almirante B, et al. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 2005; 55:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/12\">",
"      Pfaller MA, Diekema DJ, Messer SA, et al. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J Clin Microbiol 2003; 41:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/13\">",
"      Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/14\">",
"      Bennett JE. Echinocandins for candidemia in adults without neutropenia. N Engl J Med 2006; 355:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/15\">",
"      Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007; 45:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/16\">",
"      White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/17\">",
"      Marr KA, White TC, van Burik JA, Bowden RA. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin Infect Dis 1997; 25:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/18\">",
"      Oxman DA, Chow JK, Frendl G, et al. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? J Antimicrob Chemother 2010; 65:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/19\">",
"      Hernandez S, L&oacute;pez-Ribot JL, Najvar LK, et al. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 2004; 48:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/20\">",
"      Kofteridis DP, Lewis RE, Kontoyiannis DP. Caspofungin-non-susceptible Candida isolates in cancer patients. J Antimicrob Chemother 2010; 65:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/21\">",
"      Orozco AS, Higginbotham LM, Hitchcock CA, et al. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother 1998; 42:2645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/22\">",
"      Fukuoka T, Johnston DA, Winslow CA, et al. Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei. Antimicrob Agents Chemother 2003; 47:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/23\">",
"      Pfaller MA, Diekema DJ, Gibbs DL, et al. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008; 46:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/24\">",
"      Pfaller MA, Messer SA, Boyken L, et al. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J Clin Microbiol 2008; 46:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/25\">",
"      Hakki M, Staab JF, Marr KA. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 2006; 50:2522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/26\">",
"      Pelletier R, Alarie I, Lagac&eacute; R, Walsh TJ. Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med Mycol 2005; 43:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/27\">",
"      Kahn JN, Garcia-Effron G, Hsu MJ, et al. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother 2007; 51:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/28\">",
"      Spellberg BJ, Filler SG, Edwards JE Jr. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 42:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/29\">",
"      Panackal AA, Gribskov JL, Staab JF, et al. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 2006; 44:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/30\">",
"      Pfaller MA, Castanheira M, Lockhart SR, et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/31\">",
"      Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 2006; 42:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/32\">",
"      Dodgson KJ, Dodgson AR, Pujol C, et al. Caspofungin resistant C. glabrata. Clin Microbiol Infect 2005; 11 (Suppl 2):364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/33\">",
"      Thompson GR 3rd, Wiederhold NP, Vallor AC, et al. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother 2008; 52:3783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/34\">",
"      Costa-de-Oliveira S, Marcos Miranda I, Silva RM, et al. FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy. Antimicrob Agents Chemother 2011; 55:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/35\">",
"      Pfeiffer CD, Garcia-Effron G, Zaas AK, et al. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 2010; 48:2373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/36\">",
"      Cant&oacute;n E, Pem&aacute;n J, Gobernado M, et al. Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob Agents Chemother 2004; 48:2477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/37\">",
"      Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/38\">",
"      Colombo AL, Ngai AL, Bourque M, et al. Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database. Antimicrob Agents Chemother 2010; 54:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/39\">",
"      Pfaller MA, Diekema DJ, Gibbs DL, et al. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008; 46:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/40\">",
"      Pasquale T, Tomada JR, Ghannoun M, et al. Emergence of Candida tropicalis resistant to caspofungin. J Antimicrob Chemother 2008; 61:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/41\">",
"      Garcia-Effron G, Kontoyiannis DP, Lewis RE, Perlin DS. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother 2008; 52:4181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/42\">",
"      Hawkins JL, Baddour LM. Candida lusitaniae infections in the era of fluconazole availability. Clin Infect Dis 2003; 36:e14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/43\">",
"      Girmenia C, Pizzarelli G, Cristini F, et al. Candida guilliermondii fungemia in patients with hematologic malignancies. J Clin Microbiol 2006; 44:2458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/44\">",
"      Pfaller MA, Diekema DJ, Mendez M, et al. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol 2006; 44:3551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/45\">",
"      Ells R, Kock JL, Pohl CH. Candida albicans or Candida dubliniensis? Mycoses 2011; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/46\">",
"      Gafter-Gvili A, Vidal L, Goldberg E, et al. Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin Proc 2008; 83:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/47\">",
"      Abele-Horn M, Kopp A, Sternberg U, et al. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection 1996; 24:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/48\">",
"      Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/49\">",
"      Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/50\">",
"      Shorr AF, Wu C, Kothari S. Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei. J Antimicrob Chemother 2011; 66:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/51\">",
"      Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/52\">",
"      Betts R, Glasmacher A, Maertens J, et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer 2006; 106:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/53\">",
"      Anaissie EJ, Vartivarian SE, Abi-Said D, et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996; 101:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/54\">",
"      Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/55\">",
"      Graybill JR. Voriconazole for candidosis: an important addition? Lancet 2005; 366:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/56\">",
"      Betts RF, Nucci M, Talwar D, et al. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009; 48:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/57\">",
"      Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012; 54:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/58\">",
"      Malani A, Hmoud J, Chiu L, et al. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis 2005; 41:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/59\">",
"      Rex JH, Pfaller MA, Barry AL, et al. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob Agents Chemother 1995; 39:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/60\">",
"      Bodey GP, Mardani M, Hanna HA, et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002; 112:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/61\">",
"      Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/62\">",
"      Rex JH, Bennett JE, Sugar AM, et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis 1995; 21:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/63\">",
"      Asmundsd&oacute;ttir LR, Erlendsd&oacute;ttir H, Gottfredsson M. Improving survival of patients with candidaemia: analysis of prognostic factors from a long-term, nationwide study in Iceland. Scand J Infect Dis 2005; 37:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/64\">",
"      Labelle AJ, Micek ST, Roubinian N, Kollef MH. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008; 36:2967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/65\">",
"      Stamos JK, Rowley AH. Candidemia in a pediatric population. Clin Infect Dis 1995; 20:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/66\">",
"      Nucci M, Anaissie E. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis 2002; 34:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/67\">",
"      Nucci M, Anaissie E, Betts RF, et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis 2010; 51:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/68\">",
"      Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998; 104:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/69\">",
"      Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis 2001; 33:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/70\">",
"      Raad I, Hanna H, Boktour M, et al. Management of central venous catheters in patients with cancer and candidemia. Clin Infect Dis 2004; 38:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/71\">",
"      Brass EP, Edwards JE. Should the guidelines for management of central venous catheters in patients with candidemia be changed now? Clin Infect Dis 2010; 51:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/72\">",
"      Clancy CJ, Nguyen MH. The end of an era in defining the optimal treatment of invasive candidiasis. Clin Infect Dis 2012; 54:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/73\">",
"      Walsh TJ, Rex JH. All catheter-related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular catheters. Clin Infect Dis 2002; 34:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/74\">",
"      Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 2006; 43:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/75\">",
"      Schuster MG, Edwards JE Jr, Sobel JD, et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 2008; 149:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/76\">",
"      Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/77\">",
"      Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49:3640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/78\">",
"      Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002; 113:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/79\">",
"      Kollef M, Micek S, Hampton N, et al. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis 2012; 54:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/80\">",
"      Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/13/29914/abstract/81\">",
"      Leroy O, Gangneux JP, Montravers P, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009; 37:1612.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2430 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.111.122.2-0C8C6D5D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_13_29914=[""].join("\n");
var outline_f29_13_29914=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H331738097\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTIFUNGAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Azoles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Echinocandins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H230582206\">",
"      Amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUSCEPTIBILITY PATTERNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      C. albicans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      C. krusei",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      C. glabrata",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      C. parapsilosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H230584204\">",
"      C. tropicalis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1392678\">",
"      C. lusitaniae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1392705\">",
"      C. guilliermondii",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1392759\">",
"      C. dubliniensis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H230580859\">",
"      Antifungal therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Azoles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Echinocandins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H230583038\">",
"      - Amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H883985359\">",
"      - Comparison of trial data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Choice of initial antifungal agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H230581751\">",
"      Non-neutropenic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H230581758\">",
"      Neutropenic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H323853372\">",
"      C. parapsilosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      C. glabrata and C. krusei",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H323853594\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H230581818\">",
"      - Oral step-down therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H230581125\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H230581214\">",
"      - Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Ophthalmologic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Catheter removal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H230581572\">",
"      EMPIRIC ANTIFUNGAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H230580774\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2430\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2430|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/33/38428\" title=\"table 1\">",
"      Candida spp susceptibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/28/9677\" title=\"table 2\">",
"      Treatment of candidemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=related_link\">",
"      Amphotericin B nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/21/29018?source=related_link\">",
"      Antifungal susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40566?source=related_link\">",
"      Candida endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39559?source=related_link\">",
"      Candida infections of the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11671?source=related_link\">",
"      Candida osteoarticular infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=related_link\">",
"      Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=related_link\">",
"      Epidemiology and pathogenesis of candidemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13849?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10071?source=related_link\">",
"      Hepatosplenic candidiasis (chronic disseminated candidiasis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42071?source=related_link\">",
"      Overview of Candida infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=related_link\">",
"      Pharmacology of amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9338?source=related_link\">",
"      Pharmacology of echinocandins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adults with hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40760?source=related_link\">",
"      Treatment of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3336?source=related_link\">",
"      Treatment of candidemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39112?source=related_link\">",
"      Treatment of endogenous endophthalmitis due to Candida species",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20793?source=related_link\">",
"      Treatment of oropharyngeal and esophageal candidiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_13_29915="Lab findings in hypothermia";
var content_f29_13_29915=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Laboratory findings in hypothermia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Arterial blood gas",
"      </td>",
"      <td>",
"       Metabolic acidosis, respiratory alkalosis, or both",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Electrolytes",
"      </td>",
"      <td>",
"       No consistent abnormality",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Glucose",
"      </td>",
"      <td>",
"       Increased, decreased, or no change",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       White blood cell and platelets counts",
"      </td>",
"      <td>",
"       Decreased due to splenic sequestration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hemoglobin, hematocrit",
"      </td>",
"      <td>",
"       Increased due to hemoconcentration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lipase",
"      </td>",
"      <td>",
"       May be increased due to hypothermia-induced pancreatitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prothrombin and partial thromboplastin times",
"      </td>",
"      <td>",
"       Increased in vivo due to inhibition of coagulation cascade, despite normal reported values",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Electrocardiogram",
"      </td>",
"      <td>",
"       Prolongation of PR, QRS, QT intervals",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       ST segment elevation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       T wave inversions; Osborn J wave",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Atrial fibrillation or sinus bradycardia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chest radiograph",
"      </td>",
"      <td>",
"       Aspiration pneumonia, vascular congestion, pulmonary edema",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Mechem CC. Hypothermia and Hyperthermia. IN: The Intensiive Care Unit Manual, Lanken, PN, Manaker,S, Hanson, CW III (Eds), WB Saunders, Florida 2000.p.627.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_13_29915=[""].join("\n");
var outline_f29_13_29915=null;
var title_f29_13_29916="Contact allergens children";
var content_f29_13_29916=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common contact allergens in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Allergen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"       <td class=\"subtitle1\">",
"        Source",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical distribution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urushiol",
"       </td>",
"       <td>",
"        Poison ivy, oak, sumac",
"       </td>",
"       <td>",
"        Poison ivy, oak, sumac",
"       </td>",
"       <td>",
"        Linear pattern",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nickel",
"       </td>",
"       <td>",
"        Metal",
"       </td>",
"       <td>",
"        Jewelry, buckles, clothing snaps",
"       </td>",
"       <td>",
"        Earlobes, neck, wrist periumbilical, base of fingers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neomycin",
"       </td>",
"       <td>",
"        Topical antibiotic",
"       </td>",
"       <td>",
"        Topical medications",
"       </td>",
"       <td>",
"        Sites of healing wounds, ear canal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potassium dichromate",
"       </td>",
"       <td>",
"        Tanning agent",
"       </td>",
"       <td>",
"        Leather, shoes",
"       </td>",
"       <td>",
"        Dorsum of feet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thimerosal",
"       </td>",
"       <td>",
"        Preservative",
"       </td>",
"       <td>",
"        Topical medications",
"       </td>",
"       <td>",
"        Face and eyelids, healing wounds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Balsam of Peru",
"       </td>",
"       <td>",
"        Fragrance",
"       </td>",
"       <td>",
"        Perfumes, soaps, cosmetics, moisturizers",
"       </td>",
"       <td>",
"        Axillae, neck, face, eyelids, site of application of moisturizer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Formaldehyde",
"       </td>",
"       <td>",
"        Preservative",
"       </td>",
"       <td>",
"        Topical medications,creams, lotions, shampoo",
"       </td>",
"       <td>",
"        Face, eyelids, axillae, hairline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quaternium 15",
"       </td>",
"       <td>",
"        Preservative",
"       </td>",
"       <td>",
"        Topical medications, creams, lotions",
"       </td>",
"       <td>",
"        Face, eyelids, axillae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colophony",
"       </td>",
"       <td>",
"        Sticky substance from pine and spruce tree trunks",
"       </td>",
"       <td>",
"        Adhesives, glues, sealants, cosmetics, soaps",
"       </td>",
"       <td>",
"        Axillae, neck, face, eyelids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        p-tert- butylphenol formaldehyde",
"       </td>",
"       <td>",
"        Resin",
"       </td>",
"       <td>",
"        Leather glues, adhesives, watch straps",
"       </td>",
"       <td>",
"        Shoes, tape-distribution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wool alcohol",
"       </td>",
"       <td>",
"        Lanolin",
"       </td>",
"       <td>",
"        Soaps, emollients, topical medications, cosmetics",
"       </td>",
"       <td>",
"        Face, hands",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Hogan, PA, Weston, WL. Allergic contact dermatitis in children. Pediatr Rev 1993; 14:240.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_13_29916=[""].join("\n");
var outline_f29_13_29916=null;
var title_f29_13_29917="Direct-to-consumer genetic profiling services";
var content_f29_13_29917=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Direct-to-consumer genetic profiling services",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Genotyping",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Genome sequencing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        <p>",
"         23andme",
"        </p>",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         Navigenics",
"        </p>",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         deCODE genetics",
"        </p>",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         Pathway Genomics",
"        </p>",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         Genetics Testing Laboratories (GTL)",
"        </p>",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         Knome",
"        </p>",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         Illumina",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"        <strong>",
"         URL",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         <a href=\"file://www.23andme.com\">",
"          www.23andme.com",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <a href=\"file://www.navigenics.com\">",
"          www.navigenics.com",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <a href=\"file://www.decodeme.com\">",
"          www.decodeme.com",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"        <a href=\"file://www.pathway.com\">",
"         www.pathway.com",
"        </a>",
"       </td>",
"       <td>",
"        <p>",
"         <a href=\"file://www.gtldna.com\">",
"          www.gtldna.com",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"        <a href=\"file://www.knome.com\">",
"         www.knome.com",
"        </a>",
"       </td>",
"       <td>",
"        <p>",
"         <a href=\"file://www.everygenome.com\">",
"          www.everygenome.com",
"         </a>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Platform/variant content",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         SNP genotyping microarray",
"        </p>",
"        <p>",
"         ~578,000 SNP",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Selected SNP panel",
"        </p>",
"        <p>",
"         120 SNP",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         SNP genotyping microarray",
"        </p>",
"        <p>",
"         ~1.1 million SNP",
"        </p>",
"       </td>",
"       <td>",
"        Selected SNP panel",
"       </td>",
"       <td>",
"        Selected SNP panel",
"       </td>",
"       <td>",
"        Whole genome, or exome SNPs, &plusmn;indels, &plusmn;CNVs",
"       </td>",
"       <td>",
"        Whole genome, or exome SNPs, &plusmn;indels, &plusmn;CNVs",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Data interpretation services",
"        </strong>",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Genetic counseling services",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Yes",
"        </p>",
"        <p>",
"         ($99 general information)",
"        </p>",
"        <p>",
"         ($375 for direct consult)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Yes",
"        </p>",
"        <p>",
"         (unlimited x 1 year)",
"        </p>",
"       </td>",
"       <td>",
"        Available",
"       </td>",
"       <td>",
"        Available",
"       </td>",
"       <td>",
"        Available",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Ancestry services",
"        </strong>",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Data, no analysis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Number of traits characterized",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Carrier status: 47",
"        </p>",
"        <p>",
"         Complex traits: 174",
"        </p>",
"        <p>",
"         Drugs: 0",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Complex traits: 29",
"        </p>",
"        <p>",
"         Drugs: 12",
"        </p>",
"       </td>",
"       <td>",
"        47&nbsp;conditions",
"       </td>",
"       <td>",
"        <p>",
"         Carrier status: 76",
"        </p>",
"        <p>",
"         Complex traits: 81",
"        </p>",
"        <p>",
"         Drugs: 10",
"        </p>",
"       </td>",
"       <td>",
"        Complex traits: 28",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        Data, no analysis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Direct consumer access",
"        </strong>",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No (via MD)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No (via MD)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes&nbsp;",
"       </td>",
"       <td>",
"        Yes&nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Cost",
"        </strong>",
"        *",
"       </td>",
"       <td>",
"        $299",
"       </td>",
"       <td>",
"        $999",
"       </td>",
"       <td>",
"        $1100",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        $265 for traits",
"       </td>",
"       <td>",
"        $3750 to $4998",
"       </td>",
"       <td>",
"        $7500 to $10,000",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Based on websites, published reports, or phone-based customer service information as of April 27, 2011.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_13_29917=[""].join("\n");
var outline_f29_13_29917=null;
var title_f29_13_29918="Novel rx food allergy";
var content_f29_13_29918=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F80640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F80640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Novel immunomodulatory therapies for food allergy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Therapy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanisms of action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral immunotherapy (IT)",
"       </td>",
"       <td>",
"        <p>",
"         Decreased skin test reactivity and food-IgE, increased food-IgG, IgA",
"        </p>",
"        <p>",
"         Increased CD4+CD23high T cells",
"        </p>",
"        <p>",
"         Increased IL-10, IL-5, IFN-gamma, and TNF-alpha, and decreased IL-4 production by food-specific PBMCs",
"        </p>",
"        <p>",
"         Foxp3-positive T cells are increased until 12 months and then decrease thereafter",
"        </p>",
"        <p>",
"         Genes in the apoptotic pathways are downregulated",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Oral food tolerance or increased threshold dose of food for clinical reactions up to 6 months",
"        </p>",
"        <p>",
"         Short-term success rate about 75 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Limited long-term follow up data",
"        </p>",
"        <p>",
"         Some patients experience recurrence of symptoms if food not ingested on daily basis",
"        </p>",
"        <p>",
"         Generally safe (low rate of systemic reactions)",
"        </p>",
"        <p>",
"         Convenience of home administration of maintenance doses",
"        </p>",
"        <p>",
"         The risk of an allergic reaction to a previously tolerated dose of food is associated with physical exertion after dosing, dosing on an empty stomach, dosing during menses, concurrent febrile illness, and suboptimally controlled asthma.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sublingual IT",
"       </td>",
"       <td>",
"        Serum hazelnut-IgG4 and total IL-10 increased in treated group, no change in hazelnut-IgE",
"       </td>",
"       <td>",
"        Increased threshold dose on oral hazelnut challenge",
"       </td>",
"       <td>",
"        <p>",
"         Systemic side effects rate 0.2 percent during rush build-up phase",
"        </p>",
"        <p>",
"         No long-term follow-up",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peptide IT",
"       </td>",
"       <td>",
"        Overlapping peptides (10-20 amino-acid long) that represent the entire sequence of allergen. Binding to mast cells eliminated, T-cell responses preserved.",
"       </td>",
"       <td>",
"        Protection against peanut anaphylaxis in mice",
"       </td>",
"       <td>",
"        Improved safety profile compared with conventional IT, does not require identification of IgE-binding epitopes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Engineered recombinant protein IT",
"       </td>",
"       <td>",
"        Binding to mast cells eliminated, T-cell responses comparable to native peanut allergens",
"       </td>",
"       <td>",
"        Protection against peanut anaphylaxis in mice",
"       </td>",
"       <td>",
"        Improved safety profile compared with conventional IT, requires identification of IgE binding sites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IT with heat-killed bacteria mixed with or expressing modified proteins",
"       </td>",
"       <td>",
"        Potentiation of Th 1 and T- regulatory cytokine responses",
"       </td>",
"       <td>",
"        Protection against peanut anaphylaxis in mice, lasting up to 10 weeks after treatment",
"       </td>",
"       <td>",
"        <p>",
"         Concern for toxicity of bacterial adjuvants, excessive Th 1 stimulation, and potential for autoimmunity",
"        </p>",
"        <p>",
"         Heat-killed E. coli expressing modified peanut allergens administered rectally viewed as the safest approach for future human studies",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"         IT with immunostimulatory sequences (ISS-ODN) linked to or mixed with modified proteins",
"        </span>",
"       </td>",
"       <td>",
"        <p style=\"margin: 0in 0in 10pt;\">",
"         <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"          Potent stimulation of Th 1 via activation of antigen-presenting cells, natural killer cells, and B cells",
"         </span>",
"        </p>",
"        <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"         Increased Th 1 cytokines",
"        </span>",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"         Protection against peanut sensitization in mice",
"        </span>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"          Not shown to reverse established peanut allergy",
"         </span>",
"        </p>",
"        <p>",
"         <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"         </span>",
"        </p>",
"        <p>",
"         <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"         </span>",
"         <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"          Concern for excessive Th 1 stimulation, and potential for autoimmunity",
"         </span>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <span style=\"font-family: verdana,sans-serif; font-size: 9pt;\">",
"          Human immunoglobulin Fc-Fc fusion protein",
"         </span>",
"        </p>",
"        <p>",
"         <span style=\"font-family: verdana,sans-serif; font-size: 9pt;\">",
"         </span>",
"        </p>",
"        <p>",
"         <span style=\"font-family: verdana,sans-serif; font-size: 9pt;\">",
"         </span>",
"         <i>",
"          <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"           Zhang 2004, Kepley 2004, Zhu 2005",
"          </span>",
"         </i>",
"        </p>",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"         Fusion protein cross-links the high-affinity Fc",
"        </span>",
"        <span style=\"line-height: 115%; font-family: symbol; font-size: 9pt;\">",
"         e",
"        </span>",
"        <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"         RI and low affinity FC&gamma;RIIb receptors on mast cells and basophils",
"        </span>",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"         Fusion protein inhibits degranulation of mast cells and basophils",
"        </span>",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"         A human gamma-allergen fusion protein, the Fc-Fel d 1 fusion protein inhibited Fel d 1-mediated degranulation in purified human basophils from cat allergic patients and blocked the allergic responses in a mouse model. A similar approach can be utilized for food allergy.",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <span style=\"line-height: 150%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"          Sugar-conjugated BSA",
"         </span>",
"         <i>",
"          <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"          </span>",
"         </i>",
"        </p>",
"        <p>",
"         <i>",
"          <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"           Zhou 2010",
"          </span>",
"         </i>",
"        </p>",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"         Mannoside-conjugated BSA (Man",
"         <sub>",
"          51",
"         </sub>",
"         -BSA) targeted lamina propria dendritic cells expressing SIGNR-1 and promoted Cd4+ type 1 T regulatory cells",
"        </span>",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"         Mice sensitized with Man",
"         <sub>",
"          51",
"         </sub>",
"         -BSA were protected from anaphylaxis during an oral challenge with BSA and Man",
"         <sub>",
"          51",
"         </sub>",
"         -BSA",
"        </span>",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"         Sugar-modified food allergens might be used to induce oral tolerance by targeting SIGNR-1 and lamina propria dendritic cells.",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monoclonal anti-IgE",
"       </td>",
"       <td>",
"        Binds to circulating IgE and prevents IgE deposition on mast cells and blocks degranulation",
"       </td>",
"       <td>",
"        Improves symptoms of asthma and allergic rhinitis, provides protection against peanut anaphylaxis in 75 percent of treated patients",
"       </td>",
"       <td>",
"        <p>",
"         Subcutaneous at monthly intervals, unknown long-term consequences of IgE elimination",
"        </p>",
"        <p>",
"         Food non-specific",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Traditional Chinese Medicine (TCM)",
"       </td>",
"       <td>",
"        Down-regulation of Th2 cytokines (IL-4, IL-5, Il-13), up-regulation of TH1 cytokines (IFN-&Gamma;, IL-12), decreased allergen-IgE, decreased T cell proliferation to peanut",
"       </td>",
"       <td>",
"        Reverses allergic inflammation in the airways, protects mice from peanut anaphylaxis",
"       </td>",
"       <td>",
"        Oral, generally safe and well tolerated, ongoing studies focus on identification of the crucial active herbal components in the multi-herb formulas and establishing optimal dosing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <i>",
"         <span style=\"font-family: verdana,sans-serif; font-size: 9pt;\">",
"          Trichuris suis",
"         </span>",
"        </i>",
"        <span style=\"font-family: verdana,sans-serif; font-size: 9pt;\">",
"         ova therapy",
"        </span>",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"         Stimulation of IL-10 synthesis",
"        </span>",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"         In a mouse model of food allergy protected against food IgE -sensitization and anaphylaxis",
"        </span>",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"         Safe and afforded clinical improvement in Crohn&rsquo;s disease and ulcerative colitis; no beneficial effect in adults with allergic rhinitis",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <span style=\"font-family: verdana,sans-serif; font-size: 9pt;\">",
"          Monoclonal anti-IL- 5 antibody (mepolizumab)",
"         </span>",
"         &nbsp;",
"        </p>",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"         Reduced tenascin C (P = 0.03) and transforming growth factor beta-1 (P= 0.05) expression in the esophageal epithelial layer 13 weeks following initiation of treatment.",
"        </span>",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"         Limited improvement of symptoms",
"        </span>",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"         Well tolerated; acceptable safety profile, even at the high 1500 mg dose level. Current studies evaluate mepolizumab in children with EoE.",
"        </span>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_13_29918=[""].join("\n");
var outline_f29_13_29918=null;
var title_f29_13_29919="Contents: Genetic diseases in children";
var content_f29_13_29919=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Genetic diseases in children",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Genetic diseases in children",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Basic science",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/55/28536\">",
"           Cytogenetic and molecular genetic diagnostic tools",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/54/13159\">",
"           Polymerase chain reaction",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Congenital skeletal diseases",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/9/38040\">",
"           Osteogenesis imperfecta: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/36/26185\">",
"           Osteogenesis imperfecta: Management and prognosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Craniofacial anomalies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/8/17545\">",
"           A clinical genetics approach to microcephaly",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/18/8487\">",
"           Craniosynostosis syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/34/44581\">",
"           Facial clefts and holoprosencephaly",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/37/10841\">",
"           Overview of craniosynostosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/15/250\">",
"           Syndromes with craniofacial abnormalities",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cytogenetic abnormalities",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/57/24473\">",
"           Beckwith-Wiedemann syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/15/26874\">",
"           Clinical features and diagnosis of Down syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/42/33449\">",
"           Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/0/23562\">",
"           Congenital cytogenetic abnormalities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/27/28087\">",
"           Genomic disorders: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/58/13224\">",
"           Management of Down syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/14/34025\">",
"           Microdeletion syndromes (chromosomes 1 to 11)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/44/11978\">",
"           Microdeletion syndromes (chromosomes 12 to 22)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/17/37143\">",
"           Microduplication syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/50/10024\">",
"           Sex chromosome abnormalities",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Dermatologic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/0/24586\">",
"           The genodermatoses",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Dysmorphology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/45/19161\">",
"           Approach to congenital malformations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/13/7386\">",
"           Genetic and environmental causes of birth defects",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Glycogen storage diseases",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/48/16136\">",
"           Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/36/42564\">",
"           Glycogen branching enzyme deficiency (glycogen storage disease IV, Andersen disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/34/13861\">",
"           Glycogen debrancher deficiency (glycogen storage disease III)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/31/44530\">",
"           Lactate dehydrogenase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/43/6836\">",
"           Liver glycogen synthase deficiency (glycogen storage disease 0)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/27/20916\">",
"           Liver phosphorylase deficiency (glycogen storage disease VI, Hers disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/20/17736\">",
"           Lysosomal acid maltase deficiency (glycogen storage disease II, Pompe disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/19/43315\">",
"           Lysosome-associated membrane protein 2 deficiency (glycogen storage disease IIb, Danon disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/23/23928\">",
"           Muscle phosphorylase deficiency (glycogen storage disease V, McArdle disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/35/40500\">",
"           Other disorders of glycogen metabolism: GLUT2 deficiency and aldolase A deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/16/4356\">",
"           Overview of inherited disorders of glucose and glycogen metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/59/28596\">",
"           Phosphofructokinase deficiency (glycogen storage disease VII, Tarui disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/19/44341\">",
"           Phosphoglycerate kinase deficiency and phosphoglycerate mutase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/41/25237\">",
"           Phosphorylase b kinase deficiency",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Inborn errors of metabolism",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/56/905\">",
"           Approach to the metabolic myopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/36/21065\">",
"           Causes of metabolic myopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/10/30886\">",
"           Clinical features and diagnosis of galactosemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/6/7274\">",
"           Clinical features and diagnosis of the mucopolysaccharidoses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/45/13018\">",
"           Clinical manifestations, diagnosis, and natural history of Wilson disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/16/35082\">",
"           Complications and management of the mucopolysaccharidoses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/4/23624\">",
"           Disorders of tyrosine metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/37/13910\">",
"           Epidemiology and pathogenesis of Wilson disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/40/12937\">",
"           Gaucher disease: Initial assessment, monitoring, and clinical course",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/11/9402\">",
"           Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/59/10170\">",
"           Gaucher disease: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/26/27047\">",
"           Inborn errors of metabolism: Classification",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/58/24489\">",
"           Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/55/13177\">",
"           Inborn errors of metabolism: Identifying the specific disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/0/10250\">",
"           Inborn errors of metabolism: Metabolic emergencies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/5/36950\">",
"           Management and outcome of galactosemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/46/7914\">",
"           Organic acidemias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/60/27590\">",
"           Overview of maple syrup urine disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/58/35753\">",
"           Overview of phenylketonuria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/48/14088\">",
"           Tests used in the diagnosis of Wilson disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/11/23737\">",
"           Treatment of Wilson disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/49/20248\">",
"           Urea cycle disorders: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/49/19225\">",
"           Urea cycle disorders: Management",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neurologic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/60/23497\">",
"           Ataxia-telangiectasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/4/34889\">",
"           Clinical features and diagnosis of fragile X syndrome in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/5/22618\">",
"           Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/4/15432\">",
"           Friedreich ataxia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/31/31226\">",
"           Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/37/602\">",
"           Hereditary neuropathies associated with generalized disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/59/35770\">",
"           Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/16/43272\">",
"           Hereditary sensory and autonomic neuropathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/25/8599\">",
"           Huntington disease: Genetics and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/10/26793\">",
"           Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/8/5257\">",
"           Intellectual disability (mental retardation) in children: Evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/59/40887\">",
"           Intellectual disability (mental retardation) in children: Management; outcomes; and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/60/4038\">",
"           Krabbe disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/30/17896\">",
"           Management of children and adolescents with fragile X syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/27/42421\">",
"           Metachromatic leukodystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/21/14678\">",
"           Molecular biology and pathogenesis of von Hippel-Lindau disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/50/36650\">",
"           Neurofibromatosis type 1 (von Recklinghausen's disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/49/27414\">",
"           Neurologic manifestations of Fabry disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/0/20489\">",
"           Overview of Niemann-Pick disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/24/21895\">",
"           Overview of hereditary neuropathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/35/37433\">",
"           Overview of the hereditary ataxias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/29/32218\">",
"           Rett syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/35/29242\">",
"           The spinocerebellar ataxias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/38/34410\">",
"           Tuberous sclerosis complex: Genetics, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/36/32328\">",
"           Tuberous sclerosis complex: Management",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Renal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/59/33721\">",
"           Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/58/28584\">",
"           Autosomal dominant polycystic kidney disease in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/13/29913\">",
"           Autosomal recessive polycystic kidney disease in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/5/22618\">",
"           Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/36/7753\">",
"           Congenital and infantile nephrotic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/18/12584\">",
"           Cystinosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/56/10120\">",
"           Genetics and pathogenesis of nephronophthisis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/59/1973\">",
"           Nail-patella syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/55/12154\">",
"           Primary hyperoxaluria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/10/5287\">",
"           Williams-Beuren syndrome",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-38B64D523D-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f29_13_29919=[""].join("\n");
var outline_f29_13_29919=null;
